3Rd Annual Sachs Cancer

WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

3rd Annual 3rd February 2015 February rd 23 Conference Guide www.sachsforum.com Sachs Cancer Sachs Cancer New York Academy of Sciences • USA Academy York New Promoting Public & Private Sector, Promoting Public & Private Bio Partnering & Bio Partnering Forum Investment

Collaboration & Investment in Drug Development & Investment Collaboration 3RD ANNUAL SACHS CANCER BIO PARTNERING & INVESTMENT FORUM INVESTMENT & PARTNERING BIO CANCER SACHS ANNUAL 3RD WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u February 2015 at the New York Academy of 2015 at the New York February rd • New York Academy of Sciences • USA of Sciences Academy York • New 2015 February rd One-to-one meetings you have Should any queries about your schedule, Please bring with you a copy of your diary. the laptop situated by the meeting tables is available for your assistance. The registration desk is open from 8.00am on 23rd February although you are welcome to Please collect a copy of the agenda for information on timing and join the event at any time. room allocation for each session. Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request will endeavour to send you the requested We to [email protected] after the conference. presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT havethat copies of the slides are shown during the conference. General Information • • Sachs Associates, building upon it’s manyorganizing premier years of expertise in upon it’s building Associates, Sachs is proud to and the United States, partnering and investor meetings in Europe & Investment welcome you to the 3rd Annual Sachs Cancer Bio Partnering Forum being held on 23 . This forum bring together thought leaders from cancer is designed to Sciences. pharma and biotech to facilitate patient groups, advocacy research institutes, partnering and funding/investment. Associates like to thank our sponsors and partners who have would helped Sachs make this event possible. Promoting Public & Private Sector, Public & Private Promoting Development in Drug & Investment Collaboration 23 3rd Annual 3rd SachsCancer & Bio Partnering Forum Investment Sachs Associates are delighted to welcome you to the: are delighted to welcome you to Sachs Associates 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

For regular updates, sponsorship, presenting and attending opportunities and attending opportunities presenting sponsorship, For regular updates, regarding anyand further information contact of our future events please Silvia Kar on [email protected] 3rd Annual 3rd Summit Medtech & Diagnostics Innovations Düsseldorf • Germany 2015 • 16th November Sachs Immuno-Oncology: BD&L and Investment Forum BD&L and Investment Sachs Immuno-Oncology: 8th Annual CEO Forum & Exhibition Life Science European & Pharma Industry & Investing in Biotech Partnering Airport Hotel • Switzerland 2015 • Hilton Zurich – 04th March 03rd this exclusive and highly transactional partnering event is a must for wishing companies Back for its eighth year, engage with leading investors and forge new partnerships. to meet with their peers, the forum will provide an excellent platform to gain insight into event, Building on the success of this year’s Networking at the Forum is facilitated by Pharma industry. partnering and investment trends in the Biotech and which is available to all participants. our online 1-2-1 meeting system, The conference will feature up to 80 presentations byto mid size pharmaceutical companies looking for large leading Do not miss out on this great opportunity to meet emerging companies, strategic alliances/partners. global investors and Big Pharma representatives! at: www.sachsforum.com/zurich_elsceo15 Event details available View last year’s event at: www.sachsforum.com/mdis14 last year’s View Event details available at: www.sachsforum.com/basel15 Event details available The Summit is designed to bring together a specialist audience from leading and growth companies focused on The program will feature keynotes from industry leaders and plenary panels on alliances and Investment. M+A, The and diagnostics. company finance, venture investment and growth, industry acquisitions; public markets, subjects of regulation and reimbursement will also be covered. The program will also feature public and private company presentations focused on innovation and alliances/ Imaging, Cardiovascular, and Device companies track will cover; Oncology, The MedTech investment opportunities. with a separatetrack for Diagnostics. Surgical Devices & Implants, 29th – 30th September 2015 • Congress Center Basel • Switzerland 29th – 30th September 2015 • Congress The forum is recognised as the leading international stage for in the those interested in investing and partnering The Forum draws together an exciting cross-section biotech and life science industry and is highly transactional. money managers and analysts, late-stagecompanies with leading investors, and public of early-stage/pre-IPO, this event bio industry, designed by Supported and leading figures within Europe’s pharma licensing executives. expect over 600 delegates and 100 presenting We will once again be covered by our regular media partners. companies. Annual is again being held in Basel to be close to the largest biopharma hub in Europe and the Congress The 15th Center provides meeting space capable significant of handling several thousand one-to-one meetings as well as The Programme will feature plenary panels/workshops covering BD & Licensing in the main exhibition space. There will be significant networking opportunities at the Forum and receptions. therapeutic areas. 29th May 2015 • Chicago • USA 15th Annual Forum Biotech in Europe & Investment Global Partnering For Events DiaryEvents 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Novartis Pharmaceuticals Novartis Oncology, Head Negotiation, Business Development, VP, Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Excellentia Global Partners Managing Partner, Beth Jacobs, York. a life science focused investment bank based in New Founder and Managing Partner of Excellentia Global Partners, ING Barings and Lehman Brothers, Beth served in senior executive positions at Morgan Stanley, Prior to founding EGP, She serves of the Harvard on the Boards Furman Selz where she founded and led the International groups. Kennedy School of not for and other cultural Academy of Sciences Executive Committee, York the New Leadership Board, Women’s Government, profit institutions. Bernhard Sixt, President and CEO, ImmunID Bernhard Sixt, Dr Sixt has over 25 years of pharmaceutical industry experience in the development and commercialization of laboratory services, and Amersham (now part of GE Healthcare), and pharmaceuticals for industry leaders such as in vivo and in vitro diagnostics, CEO from 2003 until 2011. Agendia and has served as the company’s He is a co-founder of Takeda). Nycomed (now part of and a PhD from Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry University, from Ludwig Maximilians Germany. both in Munich, University, Technical the Barrett J. Rollins MD, PhD, Linde Family Harvard Medical School Professor of Medicine, PhD, Rollins MD, J. Barrett Dana-Farber Cancer Institute Chief Scientific Officer, Reserve Western and his MD and PhD from Case Amherst College, Rollins received his undergraduate degree from Dr. and a fellowship Boston, He completed internship and residency training in Internal Medicine at Beth Israel Hospital, University. Rollins has been a member of the faculty at Dana-Farber since 1989. Dr. in Medical Oncology at Dana-Farber Cancer Institute. His research examines the effects of inflammation on cancer with a recent emphasis on the genetic alterations associated with designed to obtain Rollins has helped lead a project Dr. Chief Scientific OfficerAs at Dana-Farber, childhood histiocytic diseases. Rollins is the Linde Family Professor at Dr. broad genomic profiles on all patients to the Institute who come for cancer care. American Association of a member of the American Society for Clinical Investigation, a member of the Harvard Medical School, Advancement of Science. Association for the American and a Fellow of the Physicians, Anne Altmeyer, Anne Altmeyer, Head Global NegotiationsOncology Development & Licensing (BD&L) in the in Business President, Vice Altmeyer is Anne in-license or acquire Oncology her responsibilities are to assets that can further In this capacity, Business Unit at Novartis. She also oversees the group responsible for Companion Diagnostics transactions strengthen the Novartis Oncology portfolio. and manages alliances. several ongoing in the Pharmaceutical Industryexperience of Anne has over 15 years increasing responsibilities in of in positions working Anne joined the Oncology Project Management group as a Project of Novartis in 2004 and BD&L. Development, Research, generationthe through implementationand strategiesof for Teams multidisciplinary numerous led she Project There, Leader. Anne worked as a Project Manager in various Before joining Novartis, various compounds in development and on the market. Areas at Merck & Co. Therapeutic She then performed a postdoctoral France. in Molecular Immunology from Strasbourg University, Anne received her Ph.D. Associate at Cornell University and subsequently a Research became USA, University School of Medicine, York fellowship at New from the University Anne also received a MBA and a MPH In addition to her scientific training, USA. York, New Medical College, USA. of Medicine and Dentistry of New Jersey/Rutgers, 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

”, CRC, 2014 CRC, ”, Biomarkers in Drug Development: A handbook of practice, Clinical and Statistical Considerations in Personalized Medicine ”, John Wiley, 2010 and “ and 2010 Wiley, John ”, Multiple Myeloma Reseach Foundation, Inc. Foundation, Reseach Multiple Myeloma Research, Translational Vice President, Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Claudio is a member of various national and international societies. Global Head of Immunology & Biomarkers, Pfizer Global Head of Immunology & Biomarkers, Claudio Carini, Studied Medicine in Italy and of inflammationClaudio Carini leads biomedical research in the area and personalized medicine. Completed PhD in Immunology at London (UCL), the University College trained in internal medicine and clinical immunology. London and Specialist Diplomas in Clinical Immunology Completed membership of the Royal College of Pathologists, London. Rome. School of Medicine, and Respiratory Medicine, College, Faculty King’s at ImmunologyClinical Head Global the is at Claudio Biomarkers and Hon. Pfizer and a Presently, Novartis, Wyeth, atroles senior Rome and UCL, Hopkins, Johns atpositions faculty Held Harvard, London. Medicine, of School and Roche. “Inflammation & F-NIH Biomarkers Consortium He is also presently serving in national and international scientific boards: Steering Committee; F-NIH Biomarkers Group” Working “RA F-NIH Biomarkers Consortium Steering Committee; Immunology” Group” Spond.Working “Ankylosing Consortium Biomarkers F-NIH Steering Committee; Group” Working “SLE Consortium (UK) Steering Committee; MRC, “Inflammation/ Immunology Initiative – UK RA Consortium, (UK Steering Committee; MRC, Advisory Board; NL, Amsterdam, Center, Development Biomarkers Committee; Steering Consortium, SLE “Stratified Medicine, Board of Directors The PML Consortium, of Directors and Board European Union/EFPIA” ABIRISK, IMI, medicine in autoimmune diseases. role of biomarkers and precision His research interests include understanding the publications Over 200 in national and widelyis published Claudio immunologyof in areas molecular medicine. and international peer reviewed journals. Academy York New From Biomarkers Identification to Market Entry” “Companion Diagnostics: Claudio chaired a conference on 2014 of Science, “ He co-edited two books in the field of Personalized Medicine: application and strategy Daniel Auclair, Daniel Auclair, for whom he had managed the Multiple Myeloma Genomics Initiative from 2007-2010, Prior to rejoining the MMRF in 2013, where he Auclair worked at the Broad Institute of MIT and Harvard as a senior leader in the Cancer Program, Daniel Dr. was involved with a wide range of academic and industry collaborations centered around cancer genomics and personalized medicine. where he led a number most notably at Bayer Healthcare, industry, he spent a decade in the pharmaceutical Prior to this, Auclair holds graduate and post-graduate degrees in Biochemistry and Nutrition from Dr. of cancer drug discovery efforts. the University of Montreal and conducted postdoctoral studies at the Dana-Farber Cancer Institute/Harvard Cancer Center. erck Serono Global BD, EMD Merck Head of Oncology Licensing, Catherine Pickering, Catherine Global Licensing & Business Development Oncology is the Head of & Immuno-Oncology at Merck Serono. involved in all aspects of deal making for a team of business development professionals she leads Merck In this role, forresponsible been has team The keyseveral / co-development the including deals pipeline oncology business. Serono’s and more recently the licensing deal with Symphogen Pfizer. the PDL1 deal with Threshold, co-commercialisationwith deal Catherine and alliance management spent several years in the business development organisation at Prior to this role, company)Antisoma (a UK Biotech covering both search and evaluation well as transaction execution in oncology as and Catherine worked in the Before business development career, her industrial managing their key strategic alliance with Roche. forresponsible technologywas she several where out London atspinning team in Research transfer Cancer of Institute the biotechs and creating multi asset research collaborations pharma and biotech. with The Institute of Cancer Research (a college of in medicinal chemistry from Catherine grew up in London and holds a Ph.D. the University of London) and an MBA from Henley Management College. 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Morgan, Lewis & Bockius LLP Lewis & Bockius Morgan, CEO, Immune Pharmaceuticals Inc. CEO, Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Global Prostate Cancer Alliance Global Prostate Cancer Executive Director, Darryl Mitteldorf, cancer advocacy. in men’s with over 18 years of global experience Mr Mitteldorf is a leading international patient advocate, He is also the founder first of the worlds with patentsin radiotherapy areas. and other also an inventor, Mitteldorf is Mr. private startacure.org His particular expertise is indeveloping public partnerships. cancer research crowdfunding platform, Daniel Teper, Daniel Teper, America was the Managing Director for North Teper Dr. is the founder Pharmaceuticals. and CEO of IMMUNE Teper Daniel Dr. global Strategy a and public biotechnology Consulting firm advising pharmaceutical companies and at Bionest Partners, his career at Daniel started based Partner at (now part of Monitor Group). ISO Healthcare Consulting York previously a New States Headquarters in Basel and then in the United Sandoz (now Novartis) Global where he had growing responsibilities first of Head as GSK at Europe, positions in executive senior held He development. product new and marketing sales, in OperationsCommercial OperatingChief forand President as Laboratoiresthen of and Officer France Glaxo Delagrange became President He then at Global EURO RSCG Healthcare bythrough the acquisition Synthelabo (now part of Sanofi). Daniel was where he help launch multiple industry blockbusters. a leading marketing and communication group, Worldwide, a Doctor of holds Teper Dr. Santen. which was recently acquired by Japan’s NOVA), a cofounder of Novagali (NYSE Euronext: Pharmacy degreeand an MBA from INSEAD. (PharmD) from Paris XI University Senior Managing Partner, Aisling Capital LLC Senior Managing Partner, Purcell, Dennis J. he served Previously, Aisling. Advisor to CapitalAisling LLC and currently serves as a Senior Purcell is the original Founder of Mr. Purcell served as Managing Director of the Life Sciences Investment Mr. Aisling Capital, Prior to as the Senior Managing Partner. he was directly involved While at H&Q, “H&Q”) for over five years. Banking Group at Chase H&Q (formerly & Quist, Hambrecht supervisedwith over two hundred completed transactions and and advisory over $10 billion of financing assignments in the other industryand publications BioWorld cited tenure, During his biotechnologyindustries. products medical and pharmaceutical, Purcell was a Managing Director in the Mr. Prior to joining H&Q, H&Q as the leading underwriter of life sciences securities. Inc. Healthcare Group at PaineWebber, by Genetic Engineering “Biotech Hall of Fame” Purcell is a frequent commentator the industry on and has been honored in the Mr. honored as one of the top 50 Irish-American businessmen and ASAP, All-Stars list by Forbes named to the Biotechnology News, cited as one of the top 100 contributors to the biotechnology industry. Paratek Laboratories, Dynova Therapeutics, Cengent Bridge Pharmaceuticals, Pharma, Aton servedhas Purcell of a director as Mr. Advisory Council at He has served Harvard as a member of the Medical and Xanodyne Pharmaceuticals. Valentis Pharmaceuticals, Association and Biotechnology York as well as the New Association, the Board of Directors of the Biotechnology Industry School, Consulting. He also serves on the Board of L.E.K. the Irvington Institute. Accounting from the University of Delaware. in from Harvard University and his B.S. Purcell received his M.B.A. Mr. Associate, Hass, Associate, Dov practice focuses on venture capital Hass’s Mr. Business and Finance Practice. Dov Hass is an associate in Morgan Lewis’s and providing general corporate joint ventures and strategic partnerships, divestitures and mergers, acquisitions, financings, and securities representation to emerging growth and life science companies. biotechnology and pharmaceutical represents transactions Hass in companies Mr. practice, his of part significant a As supply and licensing transactions, negotiationas the such of strategic and structuring collaborations, and other alliances He also advises companies from a broad range of and joint ventures. co-promotion arrangements, distribution arrangements, industries on general corporate and transactional matters. he was a conference Prior to attending law school, from Fordham University School of Law in 2005. Hass earned his J.D. Mr. where he produced conferences for the biopharmaceutical division, director for the Institute for International Research’s served Hass also a healthcare investment banking analyst as in the private Mr. biotechnologyand pharmaceutical industries. where he focused on the biotechnology industry. Thalmann, placement group of Ladenburg 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Actinium Pharmaceuticals, Inc. , Actinium Pharmaceuticals, COO Cicic, Dragan He joined the company in 2005 and previously (ATNM). Inc. Actinium Pharmaceuticals, Draganand CMO of Cicic is the COO from the position of Project ATNM Cicic joined Dr. Inc. Actinium Pharmaceuticals, Director with held the position of the Medical a life sciences strategic and transactional group consulting focused on emerging biotech, Inc., Technologies Director of QED business and strategic Cicic prepared those clients plans on behalf of Dr. devices companies. pharmaceuticals and medical He also represented corporate private and investors in identifying acquisition and/or funding. and assisted them in raising structuring and consummating deals. investment targets and negotiating, from received his M.B.A. and The Belgrade University, Cicic graduated at as a Medical Doctor from the School of Medicine Dr. He was also a Nieman Fellow at Harvard University. The University of Pennsylvania. Wharton School at Chairman and CEO, Erytech Pharma Chairman and CEO, Gil Beyen, TiGenix co-founder Gil was the and CEO of than as Chairman and CEO in 2012. first as Chairman, Before joining ERYTECH, Little Arthur D. he was the head of the Life Sciences division of the Before that, TIG BB) for 12 years. (NYSE Euronext: He received an MS degree in Bioengineering from the University of Louvain (Belgium) and consultancy company in Brussels. an MBA from the University of Chicago (USA). Dr. Kern is currently Senior Director of External Scientific Affairs at Daiichi Sankyo where he is responsible for identifying and Kern is currently Senior Director of External Scientific Dr. research collaboration and external opportunities in Oncology. partnering, evaluating in-licensing, Adelson Medical Research Head of ProgramIn his previous position as Scientific Officer and Development for Oncology at the a portfolio he developed collaborative of interactive translational and research programs in ovarian cancer, Foundation, lymphomakeyand lung cancer involving leaders at opinion major academic research and Cancer Centers melanoma, he as Senior Director of Oncology at Lexicon Genetics, Prior to that, Australia and Israel. Europe, throughout the U.S., implemented novel approaches to oncology identification drug target and validation and was charged with advancing targeted anticancer therapeutics. The academic portion of his career primarily establishing involved and directing a basic and translational research program on molecular and cellular mechanisms underlying breast cancer progression to antiestrogen-resistant and metastatic He began this program first as a Senior Staff of the Medicine Branch of Fellow in the Breast Cancer Section phenotypes. the Nationalsubsequently Cancer Institute and at as a faculty member the Lombardi Cancer at Georgetown University and as Director and Department Head of Biochemistry and Molecular Biology at Institute in Birmingham, the Southern Research he also had program and While there, Endowed Chair in Cancer Biology. Weil Adolph Alabama where he also held the NIH-Designated Comprehensive Alabama at Birmingham’s University of executive oversight leadership roles within the He also has a history of extensive serviceProgram. Cancer on federal basic Women’s Cancer Center as co-leader of their science or small business oncology-related grantpanels. review in Microbiology from Rutgers degree in Biological from Rutgers College and his Ph.D. Sciences He received his bachelor’s University and his postdoctoral training in Cellular and Molecular Biology at the NYU Medical Center. Daiichi Sankyo Inc. Sankyo Daiichi Affairs, Senior Director of External Scientific Kern, Francis 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Argos Therapeutics, Inc. Therapeutics, Argos President & CEO, Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Jeff Abbey, Jeff Abbey, Therapeutics and a member of the board Argos Abbey has served as President and Chief Executive Officer of Jeffrey D. Argos from September 2002 to FebruaryAbbey served in various other positions at Mr. of directors since February 2010. of Business Development from FebruaryVice President 2004 to January Business 2009 and as Chief including as 2010, Vice President of Abbey served as Mr. Therapeutics, Argos Prior to joining JanuaryOfficer from February 2009 to 2010. from 1999 to 2001. an information technology company, Appliance Network, Business Development and Finance at Internet in A.B. Abbey received an Mr. from 1994 to 1999. a corporate law firm, LLP, Abbey was a partner at Eilenberg and Krause, Mr. Virginia. from the University of and J.D. mathematical economics from Brown University and an M.B.A. Limited S.R.One President, Jens Eckstein, and appointed CEO Entrepreneur-in-Residence Partner, Venture TVM Capital where he was a Eckstein comes to SR One from Dr. TVMs Boston life sciences practice where he he was a General Partner in to that, Prior and President of SelectX Pharmaceuticals. Therapeutics and a Director Thrasos He is currently of Chairman of the Board of Directors investments. focused on earlier-stage Enanta Pharmaceuticals, Pharmaceuticals, He also was a member of the Board of Directors for CoNCERT Alios BioSciences. at Advisor to Sirtris Pharmaceuticals. and an Therapeutics, Anchor Rapid Micro Biosystems, SelectX Pharmaceuticals, HavenNorth and a biotechnology start-up company focusing hearing loss, on Pharmaceuticals, Akikoa founderthe was Jens of drug discovery Jens led programs at Enanta Pharmaceuticals, TVM Capital, Prior to joining a life science IT company. Systems, Inc. and Mitotix, Inc. Advisor to the Jens is an He is the author of multiple scientific publications and holds several issued and pending patents. of BioHealth Innovation a Board Member (BHI) and a Kauffman Fellow. Alzheimer Research Forum (ARF), Massachusetts. Jens is the father of three teenagers and lives with his family in Dover, Takeda Oncology Takeda Business Development & Clinical Intelligence, Senior Medical Director, Fingert, J. Howard Director for is Senior Medical Clinical Intelligence and Business Development in the Dept of Internal and M.D, Howard Fingert, Area Head for Oncology the Dept of Medical and in Therapeutic He was formerly the Oncology. Takeda External Innovation for Affairs, Regulatory With over 20 years biotech/pharma industry experience in Clinical Development, Analyses at Pfizer. Scientific supporting responsibilities have spanned diverse academic and Industry partnerships, Howard’s and Business Development, certified in Oncology Board and and other indications. Immunotherapy, multiple successful product registrations in Oncology, 1-3 phases in experience published with schools medical Tufts atwere positions faculty prior his Harvard and Hematology, He also serves as the current Industrymanagement. and clinical risk Representative to the FDA pharmacology, clinical trials, Industry providing guidance to multiple sponsors seeking marketing authorizationAdvisory (ODAC), Committee Oncology Drugs for drugs or biologic products. Pfizer Oncology, Head of Strategic Partnerships, Research Naeve, Greg R&D efforts External for the Cancer Immunotherapy program. Naeve is currently the Rinat Lead and Head of Pfizer’s Dr. for In this role Greg is responsible liaising with Pfizer America. in the Northwest regionHe is also head of global scouting of North Pfizer he Prior to strategicand institute identify Scientists to partnerships that technologyinternal address pipeline needs. and a firm focused on The Column Group, worked as a venture capitalist fund, with the San Francisco-based life science venture Prior to that Chief he was the President and creating biotechnology to develop novel therapeutics companies and technologies. a company he co-founded develop a molecular detection platform to with applications Biosystems, Scientific Officer of Parallax Amgen working Beforehe held positions at Parallax Neurocrine Biosciences and in pre-clinical drug discovery and diagnostics. Biochemistryin Southern of University the from Ph.D. his received He therapiesnew develop to for neurodegenerative disorders. California. 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer The Leukemia and Lymphoma Society and Lymphoma The Leukemia Chief Scientific Officer, Lee Greenberger, Lee has over 25 years experience in Oncology Research and Development. His responsibilities Lymphoma Society. Scientific Officer of the Leukemia and Lee has been Chief Since September 2013, including a grant portfolio with 320 active focus on planning and executing the strategy for all LLS research programs, as well as other research initiatives. with over 15 opportunities, Acceleration Program (TAP) Therapy the projects, Dr. Greenberger guides LLS’s efforts to translate innovative research into clinical trials that ultimately will pave the way for Greenberger guides LLS’s Dr. The total annual budget for these activities is approximately $75 M. new therapies to treat blood cancers. Greenberger was global head of search and diligence for oncology and immunology at Bristol- Dr. Immediately prior to LLS, SquibbMyers foropportunities examined he oncologystrategywhere business 200 the over set helped and companies for he served for six years as vice president for research at Enzon Pharmaceuticals Prior to that, oncology and immunology. and analytical chemistry process development, toxicology, where he was responsible for pre-clinical pharmacology, Lee held positions of increasing Prior to Enzon, efforts associated with the discovery and development of oncology assets. where he began his industry Wyeth Pharmaceuticals, responsibility in the research organizations of Johnson & Johnson and givenwas He President’s the Wyeth. laterwas which byacquired Laboratories, Cyanamid/Lederle American at1990 in career Wyeth. for his work at Award He has done from Emory University. degree the University of Rochester and a Ph.D. from Greenberger holds a bachelor’s Dr. Greenberger has Dr. Albert Einstein College of Medicine. post-doctoral work at Columbia University and was on faculty at the during his research career. mostly focused on oncology, produced more than 85 publications, Head of Academic Relations & Collaborations, Roche Head of Juan Carlos Lopez, degree He obtained his first on Biomedical Research at the in 1967. México, Juan Carlos López was born in Oaxaca, degree from Columbia his Ph.D. Juan Carlos got majoring in neuroscience. Autónoma de México, Universidad Nacional He then carried out studying synaptic in neuronal cultures. plasticity in the laboratory of Eric Kandel, York) University (New During this period, studying presynaptic release. mechanisms of transmitter postdoctoral work at the Instituto Cajal (Madrid), with which he won the Algar Editorial), de la Memoria”, Telar Juan Carlos wrote a book on the neurobiology of memory (“El Juan Carlos left experimental research to become Two years later, of Scientific Dissemination in 1998. Award IV European to become the Chief Editor of York he returned to New In January 2004, Editor of Nature Reviews Neuroscience in London. Nature Medicine. Academic Relations and Collaborations at industry Juan Carlos left the publishing to become Head of In February 2014, fosteringwith charged are companyteam his his of and interactions he academic with role, this In Hoffmann-LaRoche. advance of translationalinstitutions worldwide with the aim of promoting the research and the discoverynew medicines. of Spanish a Advisory and of the Board of Directors of Noscira, Board Juan Carlos has also served as a member of the Scientific an of the Eureka Institute, He is member of the Board of Directors biotechnology company interested in neurodegeneration. international initiative that aims to promote translational research by fostering the education of MDs and PhDs interested in non-profit organization and of the Board of Directors of Keystone Symposia, bridging the gap between bench and bedside, prestigiousdevoted to the advancement of science through its series of conferences. Merck & Co., Inc. & Co., Development and Licensing, Merck Business Vice President, Ji Li, Li is overseeing Merck’s Dr. In this position, Assessment. LateVP BD&L and Head of stage Merck in 2013 as Ji Li joined Dr. Li held the Dr. to joining Merck, Prior TAs. global effort of all late in the assessment stageacross all partnering opportunities evaluation search and function where he was leading the company’s Amgen External R&D at position of Executive Director, Li was Dr. career, business development Prior to his forproduct-related all worldwide. transactions development business from Shanghai Li holds a B.S. Dr. inflammatory and metabolic diseases. Amgen in the area of bone, a discovery at scientist in NYC. from Mount Sinai School of Medicine and Ph.D. Medical University in China 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Site Head, New York and Boston Centers for Therapeutic Innovation, Pfizer for and Boston Centers York New Site Head, Leigh Zawel, the site head in in addition to being In 2014, office. work in the Boston Leigh Zawel joined Pfizer in 2013 to lead CTI’s Dr. Zawelthe oncology was site lead at Merck Dr. Before CTI, office. York New Zawel became site head to CTI’s Dr. Boston, for he was responsible drug discovery efforts focused identification on the In this role, Research Laboratories Boston. (MRL) where Zawel worked previously at Sanofi-Aventis, Dr. of development candidates for programs in the oncology franchise. where he was an Oncology and Novartis Institutes for Research/Oncology, Biomedical Biology, he was Director of Cancer Zawel has a deep backgroundand validatingin identifying oncology drug drug targets and in transitioning Dr. Group Leader. discovery programs lead optimization through to Phase 1 clinical trials. laboratory in the of Danny and characterized components of the Reinberg where he identified Zawel earned his Ph.D. Dr. Vogelstein laboratory postdoctoral training was in the of Bert Zawel’s Dr. RNA Polymerase II basal transcription machinery. Zawel also holds a MS in Bacteriology from Dr. TGFB signaling in cancer. and Ken Kinzler and focused on dysregulation of He has published more than 30 scientific as well as a BS in Biology from Rutgers University. Wisconsin, the University of biomarker utility and gene combinations, drug on 45 patentsan author He is also matter, covering chemical publications. TGFB signaling. inflammation and function in areas of apoptosis, Lisa Ricciardi, SVP CorporateDevelopment, & Business Foundation Medicine Lisa Ricciardi, FoundationRicciardi joined Lisa July Medicine in and specialty pharmaceutical global of experience in broad range with a 2014 She has successfully collaborated with and healthcare services. management, pharmacy benefits, commercial operations, she has played and a key role at the board Europe and Japan, an extensive network of industry leaders in the United States, and executive levels on strategic launches. transactions and product a full-service Ricciardi previously served pharmacy to the specialty pharmacy division of Davita as a consultant RX, Ms. was senior vice president of US and international business development at Prior to this role, specializing in renal care. She a held numerous senior Ventures. Health Woodlands a venture partner at and was Essex Inc., Medco Health Solutions, closing more than division, including senior vice president in the licensing and development management positions at Pfizer, as well as managing key several product launches in 25 transactions with multinational firms and biotechnology companies, the global pharmaceuticals division. and a director with Chimerix Ireland, PLC in Dublin, She is currentlyof United Drug Group, a member of the Board of Directors Ricciardi Ms. was previously Lisa a member of the Board of Directors at Sepracor. North Carolina; in addition, in Durham, University. Wesleyan degree with honors from earned an MBA from the University of Chicago and a bachelor’s Melanoma Alliance Research Chief Science Officer, Louise M. Perkins, Officer in 2013 where she is responsible Alliance (MRA) as Chief Science for Perkins joined the Melanoma Research Dr. strategy scientific to eliminate suffering and death due to melanoma. and implementationdevelopment the of the MRA’s drug discovery of novel therapeutic and advancement Her interests center on translational research including genomics, OfficerScientific Chief was Myeloma Research Foundationshe Multiple the at (MMRF) MRA, the joining to Prior approaches. for five years following a research career of 16 years at two major pharmaceutical companies. philanthropyventure of its expansion the continued led including its Biotech Perkins investments Dr. atWhile MMRF, the Genomics forresponsible was she the MMRF’s of the expansion addition, In Fund programs. and Clinical Award Investment Initiative first the sequenced which has comprehensively genome in 2009 and myeloma tumor analyzed 250 myeloma patient Perkins led the development Dr. More recently, samples with an array of genomic technologiesnext-gen sequencing. including which CoMMpasssm, 1,000 patient longitudinal study, of the genomics and data sharing strategy underpinning the MMRF’s dataaims to develop new targets and biomarkers through deep clinical and molecular capture and analysis. where CT, Haven, West Perkins was Director of Cancer Research at Bayer Pharmaceuticals in Dr. Prior to joining the MMRF, including Nexavar® and other innovative signal she contributed to advancing novel targeted therapies toward clinical study, she also served as the Director of Research Licensing and was responsible for While at Bayer, transduction inhibitors. she led a cancer research group Prior to joining Bayer, oncology licensing activities in support of cancer research programs. participatedshe early-stageseveral in research role, this In NJ. atKenilworth, in Institute Research Schering-Plough the programs including novel target-finding research using human genomics data. 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Edison Group Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Mike Rice, Senior Consultant, Defined Health Rice, Mike Mike has participated on project teams and managed projects pertaining to Since joining Defined Health in 2005, as well as those focused on complex therapeutics oncologytherapeutic and a variety of other areas, disease, cardiovascular such as protein and gene‐based therapies for monogenetic diseases. as Strategic Business Most recently, Mike brings to Defined Health over 10 years of experience as a biotech entrepreneur. technical knowledge and business analytics Mike combined to evaluate Pharmaceuticals, Tapestry Analyst for Development He was previously involved in translational research early stage development pipelines for partnering and licensing efforts. Mike gained exposure to the and technology transfer as Project Leader in Genomics at the Delaware Biotechnology Institute. venture capital community as a technological founder and New Product Development Manager genomics and gene of the Inc. Kimeragen, therapy firm, Mike studied the molecular basis of cancer at the Kimmel Cancer Institute and is recognized for his extensive intellectual and molecular diagnostics, gene therapy, human DNA repair, property and publication portfolio pertaining to cancer genetics, agricultural trait improvement. Alfred Lerner School of Business and Economics, Biotechnology Degree from the Creation, Venture New Mike holds an MBA, Thomas Jefferson University and a BS in Biology from the University of Delaware. an MS in Molecular Pharmacology from Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald Managing & Senior Biotechnology Director Goldstein, Mara and senior analyst head of healthcare research covering the biotechnology with sector Mara Goldstein is a managing director, including continuum of life sciences subsectors, career in equity research spans a broad Ms.Goldstein’s Cantor Fitzgerald. Fitzgerald, Prior to joining Cantor drug delivery pharmaceuticals. and specialty major pharmaceuticals, biotechnology, Ms. Goldstein was most recently with Thomson Reuters, where she served as director of research Reuters Insight, an served where she Insight, as director of research Reuters Thomson Reuters, most recently Goldstein was with Ms. practice, healthcare research initially Goldstein was responsible for the firm’s Ms. independent research services business. director Goldstein was an executive Ms. Prior to that, and later for assumed responsibility all research activities and sectors. Bank) Alex Brown & Sons (now Deutsche worked at and she also Markets, World analystand senior pharmaceutical at CIBC York New Street Journal, Wall The in publicationsquoted has been Goldstein such as Ms. Boston (now CSFB). and CS First World ABC TV and Bloomberg and has appeared television news programs on financial such as CNBC, and Newsweek, Times degree in economics from Purdue University. She holds a bachelor’s News. Maxim joins Edison from Guidepoint Global, where he was a director of survey and tracker research, conducting extensive where he was a director of survey and tracker research, Maxim joins Edison from Guidepoint Global, than 15 years’ experience in equities to the healthcare more brings He also primarymarkets. research across healthcare Previouslyanalystwas a senior healthcare he and therapeuticsector head at Ridgemark Capital and Broadfin Capital, team. charter holder and graduated magna cum laude with a BA in Maxim is a CFA and a healthcare analyst at Mehta Partners. Economics from the University of Pennsylvania. Immunovaccine Inc. Immunovaccine CEO, Mansour, Marc He is an expert in vaccinology Administration. in biology and has completed a Master of Business Marc Mansour holds a Ph.D. development of the DepoVax™ Mansour led the clinical Dr. Since he joined Immunovaccine, and cancer immunotherapy. trials in soon entering randomized Phase II therapeutic lead DPX-Survivac, vaccine cancer platformCompany’s and the He continues to lead He represents the company to the investor and scientific communities. ovarian cancer and glioblastoma. externally and with collaborators and commercial platform, based on the DepoVax™ development of vaccines the internal partners. Senior Maxim Jacobs, Healthcare Analyst, 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

MaxCyte, Inc. MaxCyte, Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Prior to joining DFCI in 2012, Prem was involved in starting up companies and consulting for Prem was involved in starting up companies biotechnology companies 2012, Prior to joining DFCI in Alliances at Praecis Pharmaceuticals, Technology Vice President for he served as Senior From 2006 to 2007, and the NCI. Prem directed the Office where his business development efforts acquisition of the company led to the by Glaxo SmithKline. Affairs at Memorial Licensing at Harvard Medical School from 2003 to 20006 and the Office of Industrial Technology of and was Director of Business He co-founded Heartland BioTechnologies Sloan-Kettering Cancer Center from 2000 to 2003. diverse in published has Prem career, research academic his During ‘90’s. atDevelopment the in Pharmaceuticals Cadus his MSc in chemistry He received and his PhD in biological from IIT/Kanpur in India chemistry areas of biology and chemistry. from MIT. Therapeutics Ark he was in charge of establishing the operations facilities of and gene-based medicine production In addition, in Finland. Vice President 1996 to 2001 as International Paul Higham worked from Commercial Therapeutics in 2001, Ark Prior to joining where he was responsible forof international all aspects commercial plc, Metabolic and Pain at GlaxoWellcome for GI, AG of increasing responsibility with Bayerpositions marketing sales and he held various 1985 to 1996 From strategy. Applied Biology. He has a degree in becoming General Manager of Bayerfor Pharmaceuticals Sweden and Denmark. Executive Vice President, Madhusudan, Cellular Therapies, Peshwa Most recently, Inc. Therapies at MaxCyte, Cellular Vice President, currently serves as Executive Ph.D., Madhusudan Peshwa, a start-up stem cell therapy company. Vice President for Research and Development at NewNeural LLC, he was Executive Vice President of Process Sciences at Dendreon Corporation Vice President of Manufacturing and as Earlier he served as characterization and manufacture of an autologous dendritic for where we was responsible development, DNDN), (NASDAQ: characterization, of design, the areas is in His expertise lateto vaccine product from concept cell studies. pivotal III Phase and cGMP systems in the development of engineered cell and tissue products and scale-up and implementation of processes, in Chemical Engineering from the University of Minnesota Peshwa obtained his Ph.D. Dr. for biopharmaceuticals’ production. on over He is a co-author India. Kanpur, Technology, in Chemical Engineering from the Indian Institute of and his B.Tech. patent applications. issued or under review, 35 scientific publications and is a co-inventor on five, immatics biotechnologies GmbH immatics biotechnologies Managing Director, Paul Higham, he served as Director Commercial Development Previously, August 2008. Paul Higham was appointed as CEO of immatics in Therapeutics responsible for Group plc where he was commercial strategy and all business development activities. Ark at Dana-Farber Cancer Institute Dana-Farber Cancer Officer, Chief Business Development Das, Prem O. Officer is Chief Research Business Development and heads DFCI’s at Dana-Farber Cancer Institute (DFCI) PhD, Prem Das, O. is responsible for patenting made and licensing discoveries DFCI by ORTV (ORTV). Ventures Technology and of Research Office faculty and Integrative also works with DFCI Research Centers to ORTV researchers to outside company to create income. generating agreements research sponsored collaborationand opportunities relationshipsenhance corporatethe with sector, backgroundin managingof experience eight years around includes academic Prem’s research. preclinical and both clinical in research. and fifteen years in basic twelve years in biotechnology business development, technology transfer offices, 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Executive Board. Philippe has been heavily involved in financial projects with an international exposure during Before joining Nanobiotix, he has hold Dedicated to the Life Sciences industry for more than 10 years, start-up launch or innovative SME development. As consultant, Astellas Pharma. Financial and Operations senior positions to reinforce EMAE commercial effectiveness for he has provided change management for support European pharmaceutical companies during their commercial development phase. followed by a Management course at INSEAD. Assas University, Philippe holds a degree in Finances from Paris Aventis Sanofi SA and Experimental Medicine, Translational Senior Director, Raffaele Baffa, who has been involved Raffaele Baffa physician, is an experienced pharmaceutical executive and an academic and clinical Dr. in all stages of biomedical research – from bench experimentation to clinical research – for over 20 years. USA. MA, at Sanofi in Cambridge, Global Biotherapeutics, ESI, Sciences, Translational Baffa is currently the Head of Dr. he was responsible for developing and implementing strategic ESI, Sciences, Translational Prior to his position as Head of and Experimental Medicine for Translational translational and clinical plans for early stage compounds as a Senior Director of the Oncology Business Unit at Sanofi. Cancer PNAS, Jama, NEJM, mainly in highly (Cell, refereed journal Baffa of 90 papers, has been the author or co-author Dr. He is He was a Kimmel Scholar (Sidney Kimmel Foundation) in 2001. and has authored 14 book chapters. etc.), Research, and serves on editorial boards of scientific journals. also member of numerous national and international societies, CFO, Nanobotix CFO, Philippe Mauberna, international growth the within company’s the conduct to 2013 June in CFO as Nanobiotix joined has Philippe Managing Director, Office of Innovations, Technology Based Ventures, TechnologyBased Office of Innovations, Managing Director, Peter Hoang, Cancer Center Anderson MD Texas The University of he is head where Strategy Business Development & at Bellicum Pharmaceuticals, Vice President, Peter Hoang is the Senior He has over 18 years of finance and deal experience corporate development and business strategy. of business development, University The Innovations for Managingthe was he Director, Bellicum, to Prior capital. venture and banking investment in Prior to formation new venture and development effort. Cancer Center and headed the institution’s Anderson MD Texas of recently most as Managing mergers & Director and head of healthcare was a senior investment banker, he Anderson, MD Merrill Morgan, J.P. he also served in the M&A departments at Oppenheimer, Previously, acquisitions advisory for CIT Group. Anderson School of Management at the from high honors distinction with an M.B.A. He earned and Deutsche Bank. Lynch University. Yale from UCLA and a B.A. 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

GE Healthcare Advaxis Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Rowan is focused on creating new businesses and investing in digital health, data analytics and precision medicine. Prior to data analytics and precision medicine. Rowan is focused on creatingin digital new businesses and investing health, responsible was she where servedRowan DiagnosticsPrecision of Head as at Healthcare, GE team, Ventures GE the joining Rowan spent Before GE, and content. software, informatics, data, for strategy products, development to integrate lab services, where she drove development of the life science investment strategy and Ventures, 11 years as a Partner at Mohr Davidow observerand director board held and in invested Rowan science life and healthcare of spectrum a across roles area. practice ParAllele Pacific Biosciences (PACB), RainDance, HealthTap, Therapeutics, Balance Adamas (ADMS), including companies, Rowan was very early employee at Ventures, Prior to joining Mohr Davidow (ILMN). Verinata Sequenta and Personalis, (AFFX), Ph.D. a holds She InpharmaticsRosetta byacquired Managerthen Marketing (IPO’d Product a and MRK) at Genomics. Incyte and was a postdoctoral fellow at the University U.K. and first class honors degree in Biochemistry from Cambridge University, San Francisco. of California, Managing Director, Ventures, Ventures, Managing Chapman, Director, Rowan NeoStem, Inc. NeoStem, Vice-President of Oncology, Dillman, Robert O. and now holds the title of NeoStem’s Acquisition, prior to the CSC Chief Medical Officer served as CSC’s Dillman, Robert O. Dr. Oncology. Vice President, Newport in servedhas Dillman Hoagthe of Director forMedical Executive Institute the Hospital as Education, and Research Dr. position he served Prior to this of the Hoag as Executive Medical Director a position he has held since 2011. California, Beach, He has of the Hoag and was Medical Director Cancer Center from 1989-2008. Family 2008-2011, Cancer Institute from Dillman chaired Dr. Irvinealso served (“UCI”) since 1989. Professor of Medicine at as a Clinical the University of California, a past President and board Member of the International and is the Cancer Biotherapy Group from 1990 to 2002, Research Society for Immunotherapy of Cancer. Dillman has directed a cell biology research laboratory focused on patient-specific cell therapies for more than 20 Dr. antibodies, monoclonal including internationallyan is He immunotherapycancer in leader recognized approaches, years. publicationsmedical 300 than more recognized is authored and has He vaccines. cancer and IL-2, therapies, cell adoptive and kidney cancers. melanoma, (CLL), Leukemia Chronic Lymphocytic lymphoma, internationally for his work in lung cancer, America in Hematology California to be selected as one of the Best Doctors in He was the first physician in Orange County, by the Orange County Medical Year Dillman was named Orange County Physician of the Dr. In 2006, and/or Oncology. Hoag Endowed Chair of Oncology and the Grace E. first endowed chair, he received Hoag Hospital’s In 2008, Association. Award from the Society for he became one of onlyService five recipients in the world to receive the Distinguished in 2010, Immunotherapy of Cancer. Dillman received his undergraduate degree from Stanford University and medical degree from Baylor College of Medicine. Dr. and served as a in Internal Medicine atHe also completed both his internship and residency Baylor College of Medicine, San Diego Medical Center. He completed his fellowship in Hematology/Oncology at University of California, Chief Resident. A co-founder of the Immunotherapy Program at St. Lukes Medical Center and former Assistant Professor of Pathology and Lukes Medical Center and former A co-founder of the Immunotherapy Program at St. programshas led He Joined Industry he the 90s. in College, Medical Wisconsin Laboratory Medicine atof the University and U.S. conducted and designed has translationaland development property intellectual and development discovery, in internationalevaluationclinical programs IV forto I personallyphase and from products of NDA/BL dozens 5 to contributed from Bristol-Myers Squibb Advaxis where Petit joins Dr. filings and the launch of 3 major drugs in Immunology and Oncology. director of Medical Strategy for New Oncology Products (ipilimumab) program, Yervoy Medical Lead for the he was the U.S. Robert served as vice president of Clinical to joining Bristol Myers-Squibb, Prior and director of Global Clinical Research. His scientific develop immunologicfocus has been to based therapies Inc. Aesgen Development at MGI Pharma and also at Petit has a Doctorate the Ohio State from University Dr. on immunologicwith a particular emphasis oncology treatment. from Indiana State University. College of Medicine in Immunology and Medical Microbiology and a B.S. Dr. Robert Petit has over 25 years of experience in all medical and scientific aspects of pharmaceutical development. of pharmaceutical development. Robert Petit has over 25 years of experience in all medical and scientific aspects Dr. Chief Scientific Officer, Robert de Petit, 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Johnson & Johnson Innovation, Boston Innovation, Johnson & Johnson President & COO, Addario Lung Cancer Medical Institute President & COO, Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Sr. Director, Transactions, Transactions, Director, Sr. Shakti Narayan, biotechnologymedicine personalized VC-backed company a atDevelopment Business led Shakti Nodality, Previously, diagnosticsdeveloping predictive clinical and more efficient drug development approaches in cancer and autoimmune transactional sciences life practiced he and atDevelopment in Business positions held he Genentech, that, to Prior disease. Goodrich & Rosati.Wilson Sonsini law at leveraging and training in his interests transactions, Shakti has led and closed multiple life sciences During his career, He earned a PhD in BA degree Shakti earned his in Biology from Grinnell College. IP/contract law. business and science, scientist and he was a post-doctoral & the Salk Institute, Wisconsin-Madison Cellular & Molecular Biology at the University of where he earned His legal studies were completed at the University of California- Berkeley Law School, at Stanford University. a JD. Steven Young, Steven Young, a patient- Medical Institute, Addario Lung Cancer serves Operating as the President & Chief Officer of the Young W. Steven founded/-focused shared via directly centers consortium community research academic and non-profit 21 than more linking data centrally system) and managed intramural translational projects in the United States, infrastructures (biorepository, had played Young Mr. transitioning from the clinical research informationAfter technology industry, Italy and Spain. France, Director Executive its as Consortium earlyResearch and Myeloma development Multiple the the in of role evolution central a he served as Director of the National Institutes of Health-funded General Clinical Earlier still, from 2003 through 2008. Research Center at Mount Sinai School of Medicine and the Pediatric Clinical Research Center at Cornell University College City. York both in New of Medicine, WBB Securities, LLC WBB Securities, Managing Partner and President, Stephen Brozak, research firm thatand bank investment biotechnology, an the in specializes LLC, Securities, WBB of President is Brozak Steve Brozak is an award winning analyst whose research has been Mr. specialty pharmaceutical and medical device sectors. highly most regarded singled out from his peers for accuracy and performance year after year by the financial industry’s written has Brozak Mr. currentlyis research His bymonitored platforms. FactSet and StarMine the organizations. rankings in the The British Medical Journal on trends and ABC News, CNN, Forbes, articles and opinions for Businessweek-Bloomberg, BNN, appearshe and regularly commentatorguest a as Bloomberg, outlets such as television financial on sector, healthcare outspoken advocate Brozak is an for the absolute need for changes in how we research and finance our Mr. CNN and CNBC. The Navy and Marine Corps He retired as a Lieutenant Colonel from the US Marine Corps and served on healthcare system. Brozak received Mr. Retiree Council for the Secretary of the Navy where he focused retiree issues. on healthcare and other both his BA and MBA from Columbia University. Stuart has been with Oppenheimer since September 2005 as a Managing Director focusing on Life Sciences. He has Stuart has been with Oppenheimer since September 2005 as a Managing Director focusing on Life Sciences. covering a broad spectrum of equity participated in the successful completion of over 250 transactions during his career, Stuart spent five years at Leerink Swann completing numerous Oppenheimer, Prior to joining and mergers and acquisitions. He previously directed the healthcare banking transactions for Biotechnology and Specialty Pharmaceutical companies. Webber. Associate with Paine after beginning his career as a Corporate Finance Auerbach, efforts at Oscar Gruss & Son and Stuart graduated with a BS in Electrical Engineering from the University of Rochester and an MBA with honors from Columbia Business School. Raymond James Financial, Inc. Raymond James Financial, Managing Director, Stuart Barich, 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Navidea Biopharmaceuticals Navidea Officer, President and Chief Business Speakers 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer Managing Director, MPM Capital Managing Director, Foley, Todd He has focused primarily on biotech was promoted to partner in 2007. Boston office in 1999 and Foley joined MPM’s Todd managesalso Todd Valeritas. and Selexys Rhythm, OSS, Iconic, currentlyand investments serves Chiasma, of boards the on longest standing which MPM believes has been one of the industry’s strategic investment relationship with Novartis, MPM’s havingmillion to thirteen committed $200 and most prolific collaborations between venture capital and pharma, investors under a variety of creativecompanies in the biotech and healthcare IT space joint equity/strategic deal structures. Thomas H. Tulip, Thomas H. Tulip, Business Officer Vice President and Chief at Navidea served where he also as President is Executive Tulip Thomas H. Dr. Lantheus Alseres Pharmaceuticals, at has held senior leadership positions Tulip Dr. from May 2014. 2013 through December discoveryproduct spanned roles his where development, and SquibbMyers Bristol DuPont, and (BMS) Imaging, Medical Most recently, brand and alliance management and international business management. business and technology planning, While at led efforts markets for to develop a Phase III neuroimaging agent. Tulip Dr. Alseres Molecular Imaging, as President, commercialization and international management development, in the he was instrumental Alseres, and BMS prior to DuPont and successfully BMS Medical Imaging built the international business, of the highly cardiology successful nuclear franchise, Vermont, from the University of earned a B.S. Tulip Dr. led planning activities for innovativeat PET tracers Lantheus/BMS. He was a visiting scholar at Osaka University and served as University. from the Northwestern and Ph.D. and an M.S. Technology serves of the Medical Imaging on the Board of Directors Tulip adjunct professor at Northeastern University. was recently He Chairperson of the in the Molecular Imaging Group Section. Working and leads its PET Association (MITA) He served on the Board of the (IMT] and held numerous leadership positions there. Technologies Institute for Molecular was Chairperson for the Society of Nuclear Medicine (SNM) Tulip Treasurer. Academy of Molecular Imaging including as its Advisory Council on Radionuclides and Radiopharmaceuticals (CORAR) of a number Board and has been active in Corporate now servingDirectors. on its Board of committees, 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Continued... www.actiniumpharmaceuticals.com Actinium Pharmaceuticals, Inc. Pharmaceuticals, Actinium PROFILE COMPANY company biopharmaceutical developing innovative targeted York-based is a New Inc. Actinium Pharmaceuticals, radiotherapy targeted products Actinium’s payload immunotherapeutics for the treatment of advanced cancers. are based on its proprietary delivery platform for the therapeutic utilization alpha-emitting actinium-225 of antibodies. monoclonal with beta emitting radiopharmaceuticals in conjunction and bismuth-213 and certain upon approval, product candidate lead radiopharmaceutical Iomab-B is designed to be used, The Company’s commonly as bone marrow transplant. referred to in preparing patients for hematopoietic stem cell transplant, study of Iomab-B multicenter Phase 3 clinical in refractory pivotal, The Company a single, plans to conduct The AML patients over the age of 55 with a primary endpoint of durable complete remission. and relapsed 1/2 trial for is continuing its clinical development in a Phase Actimab-A, second product candidate, Company’s AML patients over the age of 60 in a single-arm multicenter trial. newly diagnosed PRODUCT PIPELINE Phase III ready Iomab-B : is being developed for combination with non-myeloablativeto conditioning (NMA) prior Iomab-B (131I-BC8), called bone marrow transplant or BMT) in older relapsed/ also hematopoietic stem cell transplantation (HSCT; refractory AML patients. and iodine-131 a novel murine monoclonal antibody, Iomab-B is a radioimmunoconjugate consisting of BC8, a pan- BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, radioisotope. This antigen makes BC8 potentially useful in targeting leukocytic antigen widely expressed on white blood cells. white blood cells in preparation for hematopoietic transplantation stem cell in a number of blood cancer acute lymphoblastic chronic myeloid leukemia (CML), including acute myeloid leukemia (AML), indications, Non-Hodgkin lymphomas (NHL) and disease (HD), Hodgkin’s chronic lymphocytic leukemia (CLL), leukemia (ALL), BC8 carries radioactivity directly to the site of When labeledradioactive isotopes, with multiple myeloma (MM). cancerous growth and bone marrow while avoiding effects radiation of on most healthy tissues. Phase I/II Actimab-A : and is AML in patients over 60, Actimab-A is a radiolabeled for antibody being developed newly diagnosed alpha-particle immunotherapy (APIT) Actinium’s Based on currently in a multicenter Phase I/II clinical trial. Actimab-A Actimab-A antibody lintuzumab consists of the CD33 linked to the actinium-225 payload. platform, has attracted support from leading experts at the prestigious and high-volume cancer treatment hospitals due specificity and ease of use. well as its potential potency, as to the potential of its safety and efficacy profile, Clinical trials are being conducted at world-class cancer institutions such as Memorial Sloan Kettering Cancer Fred Hutchinson Cancer Research University of Pennsylvania Health System, Johns Hopkins Medicine, Center, Sammons Cancer Center. A. Oncology-Baylor Charles Texas Anderson Cancer Center and now the MD Center, Actimab candidates in early are The Company expects interim Phase I/II clinical trial results in December 2014. development for other cancers. OPPORTUNITIES Iomab-B the fastest Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), The Company established an agreement with the FDA that the path to growing hospital procedure in the U.S. pivotal Phase 3 clinical study if it is Applicationcould include a single, (BLA) submission a Biologics License multicenter trial will be refractory and controlled, randomized, The trial population in this two arm, successful. The trial size was set at 150 patients with Acute Myeloid Leukemia (AML) patients the age over of 55. relapsed defined as The primary in the pivotal Phase 3 trial is durable endpoint complete remission, 75 patients per arm. a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. AML in this patient population and there There are currently no effective treatments approved by the FDA for Iomab-B has completed several physician sponsored clinical trials examining is no defined standard of care. its potential as a conditioning regimen prior to HSCT in various blood cancers including the Phase 1/2 study in patientsThe results of these studies in over 300 have demonstrated AML patients. relapsed and/or refractory expanding the the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2000 EMAIL [email protected] TELEPHONE +1 646 840-5442 ADDRESS 546 Fifth Avenue 14th Floor New York NY 10036 CONTACT Dave PhD, Kaushik J. CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.actiniumpharma.com Actinium Pharmaceuticals, Inc. Pharmaceuticals, Actinium pool to ineligible patients do not have who any viable treatment options currently; enabling a shorter and safer reducing post-transplant complications; and showing a clear survival benefit preparatory interval for HSCT; including curative potential. Actimab-A alpha emitter (Actinium-225) technology drug candidate is a promising the Company’s based on Actimab-A, currently as a frontline therapy being developed for newly diagnosed acute myeloid (AML) patients leukemia ages 60 years and older. including two with following three previous successful trials, Actimab-A is currently in an ongoing Phase I/II trial, a first-generation construct. Bismab-A, AML that develops defined as AML in the U.S., a common form of AML, The target population includes secondary usually MDS. following exposure to cytotoxic agents event in another hematologic or as a subsequent disorder, is an annual incidence of 12,000 new cases of MDS in the U.S. there American Cancer Society, According to the or approximately 3,600-6,000 secondary AML, to develop Between 30% and 50% of these new cases go on AML patients in the U.S. high risk patients ordinarily have a life expectancy of 5 or fewer months if treated with standard Elderly, The other two-thirds though only about a third of them do receive treatment because of toxicity. chemotherapy, (Haematologica 2012; Weisdorf according to Oran and with 2 months survival, receive best supportive care, 1916-24). MANAGEMENT MS Executive Chairman Sandesh Seth, CEO PhD, Kaushik Dave, CMO MD, Cicic, Dragan BD SVP, MD, Gould, David ...continued 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

t back :: next u Executive Vice President and Chief Operating Officer Executive Advaxis www.advaxis.com PROFILE COMPANY Advaxis is a clinical-stage biotechnology company developing the next generation immunotherapies. of cancer attenuated bacteria to stimulate Advaxis’ immunotherapies based on a novel platform are technology using live, the immune system to selectively target cancer cells while reducing tumor defenses. lead immunotherapyAdvaxis’ for in in Phase 1/2 development the treatment of HPV-associated ADXS-HPV, has grantedAdvaxis exclusive and anal cancer. head and neck cancer, including cervical cancer, cancers, and India. Asia ADXS-HPV in licenses for and commercialization the development of ADXS-cHER2 is an immunotherapy for the treatment that of HER2 overexpressing cancers is in preclinical development for for breast cancer and Phase 1 development canine osteosarcoma. either directly or through Advaxis has created more than 15 distinct immunotherapies based on its platform, the University of Pennsylvania, strategic collaborations of excellence such as: with recognized cancer centers the Icahn School of Medicine at Mount Sinai, the Georgia Regents University Cancer Center, Brown University, and others. MANAGEMENT President and Chief Executive Officer O’Connor, Daniel J. Vice President and Chief Scientific Officer Executive Dr Robert Petit, Mayes, Gregory T. 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2002 TELEPHONE +1 609 452 9813 EMAIL [email protected] ADDRESS 305 College Rd East NJ 08540 Princeton, CONTACT Investor Relations/ Business Development Mayes Gregory T. Chief Operating Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Argos’ internal management team and Board of Directors have extensive experience with both the science and business of to manufacturing commercial product launch and marketing, ranging from preclinical to clinical development, biotechnology, products. Inc. Therepeutics, Argos www.argostherapeutics.com PROFILE COMPANY Therapeuticsis a biopharmaceutical company focused and commercialization on the development of fully Argos Arcelis® technology personalized immunotherapies for the treatment using its of cancer and infectious diseases phase ADAPT is being evaluated in the pivotal AGS-003, most advanced product candidate, Argos’ platform. The Company is also developing a 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). currently being evaluated in a forthe treatment of HIV, AGS-004, product candidate, Arcelis®-based second phase 2 clinical trial in combination with a latency reversing drug for HIV eradication patients. in adult PRODUCT PIPLINE Platform Technology N/A - : Arcelis® Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are It is designed to overcome immunosuppression by producing a durable disease. specific to each patient’s The technology is potentially response without adjuvants that may be associated with toxicity. T-cell memory applicable to a wide range of different to overcome many diseases and is designed cancers and infectious of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. which are own dendritic cells, Arcelis® process uses only a small tumor or blood sample and the patient’s The The proprietary RNA isolated process uses collected and optimized following a single leukapheresis procedure. antigen- The activated, disease sample to program target disease antigens. dendritic cells to from the patient’s and administered via intradermal injection. plasma loaded dendritic cells are then formulated into the patient’s Phase 3 AGS-003 : fully personalized immunotherapy for cancer comprised of autologous tumor AGS-003 is an investigational, ADAPT trial for the treatment of AGS-003 is currently being evaluated in the RNA-loaded dendritic cells. international standard Phase III trial comparing is a randomized, This metastatic renal cell carcinoma (mRCC). accrual byThe trial is expected to complete the end of AGS-003 to standard therapy alone. targeted therapy plus Q1 2015. in combinationAGS-003 with sunitinib in unfavorable risk treatment with phase 2 combination trial, In it’s mRCC patients resulted in median progression free survival of 11.2 months and median overall survival of 30.2 unfavorable risk In recently published findings from the International mRCC Database Consortium, months. mRCC patients had an expected median progression survival free of 5.7 months and median overall survival of Phase II study, For the patients with intermediate (1-2 risk factors) mRCC in the Company’s risk 14.7 months. AGS-003 in combination resulted in median overall survival with sunitinib of 57.1 months or treatment with nearly 5 years. Phase 2 AGS-004 : is currently being evaluated in a phase 2 clinical trial AGS-004, Arcelis-based product candidate, Argos’ second AGS-004 development The in combination with a latency reversing drug for HIV eradication in adult patients. program is being entirely funded by a $40M NIH contract. MANAGEMENT 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 1999 EMAIL [email protected] ADDRESS Dr. 4233 Technology NC 27704 Durham, USA TELEPHONE +1 919 287 6300 CONTACT Jeff Abbey President & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u bbsnanotech.com BBS NanotechnologyBBS FINANCIAL SUMMARY Private PROFILE COMPANY EU-based biotech companyseeking to build upon its POC of 16 employees BBS Nanotech is an early-stage, BBS has a proprietary portfolio of nanoencapsulatedanimal data for cancer cancer treatment and diagnosis. BBS management and scientific easy to manufacture and biocompatible. drugs and diagnostics that safe, are advisoryinternationally board are recognized executives and oncologists years of large pharma R&D with >25 experience. PRODUCT PIPELINE POC DDS1 : pre-clinical Nanoencapsulated doxorubicin POC DDS2 : pre-clinical Nanoencapsulated epirubicin POC pre-clinical : CA1 Nanoencapsulated PET agent POC DDS3 : pre-clinical Nanoencapulated paclitaxel POC DDS4 : pre-clinical Nanoencapsulated docetaxel OPPORTUNITIES Development rights for DDS1 DDS1: DDS2 : Development rights for DDS2 Development rights for : CA1 CA1 DDS3 : Development rights for DDS3 DDS4 : Development rights for DDS4 MANAGEMENT CEO and Head of Business PhD, Jill Horowitz, CSO and Founder PhD, Janos Borbely, Alpek, MBA, Director Primus Capital Istvan Director Primus Capital PhD, Krejs, Franz Advisory Board Scientific Aachen, Head of Imaging University Hopital MD, Fabian Kiessling, Advisory Board Scientific Director of Radiology Memorial Sloan Kettering, MD, Maxine Jochelson, Advisory Board Scientific Director of Institute of Oncology University of Debrecen, MD, Zsolt Horvath, Advisory Board Scientific Vantage Oncology, Chief Medical Officer and Founder MD, Leslie Botnick, 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum EMERGING YEAR FOUNDED 2008 EMAIL [email protected] TELEPHONE +1 914 689 5804 ADDRESS 75 Sheldrake Place New Rochelle, NY 10804 USA CONTACT PhD Jill Horowitz, CEO and Head of Business WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Senior Vice President of Berg & Chief Analytics Officer of Berg Analytics Division Analytics Officer of Berg Vice President of Berg & Chief Senior Berg LLC Berg www.berghealth.com COMPANY PROFILE COMPANY Therapeutics The company Berg focuses understanding how alterations research on in metabolism relate onset. to disease has a deep pipeline of early-stage technologies in CNS diseases and metabolicthat diseases complement with use of the Berg Armed its late-stage in cancer and prevention of chemotoxicity. clinical trial activity Interrogative Biology™ discovery Berg is platform that translates biologicaltherapeutic output into candidates, well positioned for rapid commercialization of its intellectual capital. Diagnostics is at the forefront of realizing the promise of Personalized a business division of Berg, Berg Diagnostics, and lipidomics molecular technologiesThe advent of high-throughput such as metabolomics, Medicine. proteomics that carries beyond leads to fundamental understanding of disease the realm of genomics multi-model panels of molecular biomarkers are to deliver Berg’s progression and response to therapy. cardiovascular and diabetes, CNS, unprecedented accuracy in clinical testing in indications as cancer, such disease. Healthcare Analytics Artificial Intelligence in biology and medicine allows for a combination of systems biology application of Berg’s Berg Interrogative Biology™ and systems engineering on human health. leading to well defined answers integrates molecular data directly from a patient and demographic with clinical information to learn predictive The platform with actionable provides the physician information to recommend efficient and safe patterns. insurance companies with health economics analyses to develop more relevant formulary, treatment pathways, and governments with a data ecosystem for of healthcare needs of the population. financial modeling MANAGEMENT Officer Technology Co-founder of Berg & Chief President, Niven R. Narain, Vice President & Chief Operating Officer Executive Calcines, Tere Vice President & Chief Scientific Officer Senior Sarangarajan, Rangaprasad Akmaev, Slava 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2006 ADDRESS Berg LLC 500 Old Connecticut Path Framingham MA Berg LLC 1845 Elm Hill Pike Nashville TN TELEPHONE Christine Jackman +1 212 880 5379 CONTACTS Narain Niven R. CEO Media & Investor Relations Christine Jackman Ogilvy Public Relations WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Chief Financial Officer BerGenBio AS BerGenBio www.bergenbio.com PROFILE COMPANY BerGenBio is a clinical stage company biopharmaceutical focused on developing innovative drugs for aggressive, drug resistant cancers. which is The Company (EMT) biology, in understanding epithelial-mesenchymal transition is a world leader Building on this original widely recognised as a key pathway in acquired cancer drug-resistance and metastasis. biological inhibitors. is developing a promising pipeline of novel EMT insight BerGenBio its product candidatesBerGenBio intends to develop to proof of concept stage; clinical development and further subsequently commercialisation will be through strategicwith experienced global alliances and partnerships bio-pharma oncology businesses. PRODUCT PIPELINE Phase 1b / 2a BGB324: trials are on going Multiple Phase Ib clinical AXL. orally bio-available small molecule inhibitor of Highly selective, and selected Phase II trials planned for unique clinical opportunities. clinical IND enabling Pre BGB001 : in late stage preclinical development: AXL, BGB001 – is three monoclonal antibody programs against one program biopharma company has already been licensed to a specialist for forward development and commercialisation. Candidate Selection Preclinical BGB002 : it is in late stage lead optimisation This is a small molecule development program against EMT target, a novel including very aggressive negative triple Substantial preclinical data suggests multiple clinical positions, phase. breast cancer and other drug resistant cancers that to treat. are difficult MANAGEMENT Chief Executive Officer Godfrey, Mr Richard Chief Scientific Officer James Lorens, Prof. Chief Medical Officer PhD, Yule Dr Murray Mrs Marit Wick, and Discovery Technology Director of Micklem, Dr David Director of Preclinical & Biologics Kiprijanov, Dr Sergej Dr Ahmadi, Director of Business Development Khatereh 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2008 EMAIL [email protected] [email protected] TELEPHONE +47 535 01 564 ADDRESS BerGenBio AS Jonas Lies vei 91 Bergen, 5009, Norway CONTACT Mr Richard Godfrey Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Continued... Efficacy demonstrated in animal models of autoimmune disorders including rheumatoid arthritis and multiple sclerosis www.casipharmaceuticals.com Inc. Pharmaceuticals, CASI FINANCIAL SUMMARY having $11.8M cash by and smart money rate, with low burning VC’s backed by successful Strong cash position, 2014 reporting. Sept 30, PROFILE COMPANY and commercialization development companyCASI is a biopharmaceutical dedicated to the acquisition, of innovative therapeutics for cancer and other unmet medical needs addressing market with a the global (ibritumomab ZEVALIN® product pipeline includes exclusive rights to CASI’s commercial focus on China. MARQIBO® (vinCRIStine sulfate LIPOSOME injection) and Captisol-EnabledTM (propylene glycol-free) tiuxetan), development CASI’s Hong Kong and Macau). Taiwan, melphalan (CE melphalan) for greater China (including a selective angiogenic kinase inhibitor pipeline also includes its proprietary drug candidate ENMD-2076, and 2ME2 (2-methoxyestradial) currently under reformulation currently in multiple Phase 2 oncology studies, Maryland and has a wholly owned subsidiary CASI is headquartered in Rockville, and R&D development. and in the More information CASI is available on at www.casipharmaceuticals.com China. operations in Beijing, Securities and Exchange Commission. filings with the U.S. Company’s PRODUCT PIPELINE currently in multiple phase 2 trials in the US and/or ENMD-2076 A Candidate for Solid Tumors trials Canada : phase 2 clinical FGFR, VEGFR, A, Aurora inhibitor with selected inhibition of multi-targetedkinase small molecule, An orally active, proliferation and the cell cycle. Action against angiogenesis, and a Mechanism of and GF, • Pre-clinical studies demonstrated in vivoanimal models. activities in vitro and in multiple strong anti-tumor • Good pharmaceutical PK/PD property • Good safety profile. • Low cost and easy manufacturing • Multiple publications in international journals. AML. multiple myeloma and ovarian cancer, • FDA orphan drug designations in HCC, in 2009 and in China in 2013. • Strong global IP with the first patent issued in the U.S. Currently in solid tumors including: in phase 2 trials in the US and/or Canada ‒ Sarcoma (STS) ‒Ovarian clear cell carcinoma (OCCC) Tissue Breast Cancer (TNBC) ‒Soft Triple-Negative Fibrolamellar Carcinoma (FLC). of Auto-Immune Disorders : Pre-IND 2-ME2 for the Treatment anti-angiogenic and anti-inflammatory properties An orally active compound that has anti-proliferative, • • Global intellectual property • • Multiple Phase I and Phase II trials in oncology patients and Phase I in healthy subjects • Excellent safety profile • Previous clinical challenge (bio-availability in human subjects) needs to be addressed. registration for greater China market : marketing (ibritumomab tiuxetan) injection ZEVALIN® It (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. ZEVALIN® low-grade or follicular B-cell non-Hodgkin’s is indicated for the treatment of patients with relapsed or refractory, is also indicated for the treatment of patients with previously untreated follicular ZEVALIN® lymphoma (NHL). chemotherapy. complete response to first-line who achieve a partial or Lymphoma non-Hodgkin’s radiolabeled Yttrium-90 (Y-90) and rituximab, therapeutic regimen consists of two components: ZEVALIN® on the combined effect builds of a targeted biologic monoclonal antibody ZEVALIN® for therapy. ZEVALIN® for Please see www.zevalin.com augmented with the therapeutic effects of a beta-emitting radioisotope. product and safety information. ZEVALIN® we expect that gaining approval and marketed by our licensor, is already approved in the U.S. Since ZEVALIN® from local regulatory authorities for commercialization in greater China will require a shorter timeframe than clinical stage drugs. 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2012 EMAIL [email protected] +1 240 864-2643 China +86-10-6508-6067 TELEPHONE USA +1 240 864 2600 Investor Relations: China Hanhai Culture Plaza Suite 716 Building 28-1 Xiang Jun Bei Li Chaoyang District Beijing 100025 ADDRESS USA 9620 Medical Center Drive Suite 300 MD 20850 Rockville, CONTACT Ren Dr Ken K. Officer Director and Chief Executive WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u CEO, Crown Biosciences, Inc. Crown Biosciences, CEO, Chief Scientific Advisor, Director, Campbell Family Research Institute/Princess Margaret Director, Advisor, Chief Scientific Chairman, IDG-ACCEL China Fund Venture Partner Venture IDG-ACCEL China Fund Chairman, www.casipharmaceuticals.com ...continued market : marketing registration for greater China Marqibo® a formulation of vincristine sulfate, sphingomyelin/cholesterol liposome-encapsulated, Marqibo® is a novel, Marqibo® is approved by the FDA for the treatment adult patients of with Philadelphia microtubule inhibitor. chromosome-negative acute lymphoblastic (Ph-) leukemia (ALL) in second or greater relapse or whose disease Marqibo® product Please see www.marqibo.com has progressed following or more anti-leukemia therapies. two and safety information. we expect that gaining approval and marketed by our licensor, Since MARQIBO® is already approved in the U.S. from local regulatory authorities for commercialization in greaterthan China will require a shorter timeframe clinical stage drugs. market : pre-marketing registration Captisol-Enabled™ melphalan for greater China Captisol-Enabled™ melphalan is a new intravenous formulation of melphalan being investigated by our licensor is used which formulationThe avoids the use of propylene glycol, in the multiple myeloma transplant setting. as a co-solvent in the current formulation has been reported to cause renal and cardiac side- of melphalan and The use of Captisol effects that limit the abilityof intended therapeutic to deliver higher quantities compounds. technology to reformulate melphalan is anticipated for to allow longer administration durations and slower potentially enabling clinicians to avoid reductions and safely achieve a higher dose intensity of infusion rates, which we Application, CE-Melphalan is expected to be the subject of a New Drug pre-transplant chemotherapy. expect will be filed by our licensor in 2014. submit our import drug registration will application forWe CE melphalan in greater China after its approval by the FDA in the U.S. OPPORTUNITIES CASI is a gateway for U.S. As a U.S.-based company with deep presence in China, Investment Opportunity: with the assurance of a NASDAQ public fast growing pharmaceutical market, investors to tap into China’s company. in China and to addressing significant and unprecedented market opportunities Well-positioned Market: worldwide. synergiesAmerica/China and competitive advantage Model: Compelling business model with important North with efficiency and effectiveness for drug development and commercialization. A strong and growing of acquisition and internal product pipeline developed under multiple models Product: development. America motivated leadership with track record of accomplishment in both North An experienced, Management: and China. and smart money with low burning rate. VC’s backed by successful Strong cash position, Money: 2015 supporting long term value drivers in growth. Drivers: Significant defined near-term Value MANAGEMENT Dr Wei-Wu He, Mak, W. Dr Tak Toronto University of Hospital; University Professor, Kleiner Perkins Caufield & Byers China General Partner, James Huang, Inc. Spectrum Pharmaceuticals, Chairman & CEO, MD, Shrotriya, Rajesh C. Wu, Alexander Dr Y. Inc. Pharmaceuticals, CASI National Foundation for Cancer Research President, Jr., Salisbury, C. Franklin OFFICERS Director and Chief Executive Officer Dr Ken K. Ren, & Secretary General Counsel Chief Operating Officer, JD, Hu, W. Cynthia Accounting Officer Principal Finance, VP, Capitelli, B. Sara 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2012 EMAIL [email protected] TELEPHONE USA +1 240 864 2600 Investor Relations: +1 240 864-2643 China +86-10-6508-6067 China Hanhai Culture Plaza Suite 716 Building 28-1 Xiang Jun Bei Li Chaoyang District Beijing 100025 ADDRESS USA 9620 Medical Center Drive Suite 300 MD 20850 Rockville, CONTACT Ren Dr Ken K. Officer Director and Chief Executive WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ltd Cell Source www.cell-source.com – An Israeli entrepreneur who has led two successful cell therapy technology firms. He cofounded two NASDAQstem listed cell An Israeli entrepreneur who has led two successful cell therapy technology firms. – therapy companies Brainstorm (currently valued at ~$60M) and Pluristem (~$200M) CEO Itamar Shimrat, chiefly firms including at consulting with extensive international business experience, – was EVP at a leading Israeli bank, major profitabilityAmerican Express to Barclays and ranging from successful global strategy programs for Citibank, McKinsey, Airlines and Federated Department Stores Al Israel hikes at El COMPANY PROFILE COMPANY is an immunotherapyCell Source (OTCBB:CLCS) and regenerative medicine company primary whose breakthrough is the regulation of immune tolerance to effectively treatand nonmalignant blood cancers and facilitate major organ transplants, safer and more accessible bone marrow and congenital diseases, technology addresses the holy grail of the field Company’s The organs. “replace” and “repair” potentially both selectively how to tune immune response so that it tolerates reject) desirable (doesn’t foreign of immunology: threats). life-saving transplantations) while continuing to actively incursions (i.e. reject all other incursions (e.g. has demonstrated in preclinical studies the to facilitating in addition transplants, This innovative capability, ability to directly such as non-Hodgkins conditions including blood cancers address a number of severe medical treat It also has the potential to non-malignant and chronic lymphocytic leukemia. multiple myeloma, lymphoma, indications by such as sickle cell anemia and scleroderma safe bone marrow transplants available making to a lungs organ regeneration platform holds the potential to repair organs (e.g. Cell Source’s broader patient pool. body. damaged by cystic fibrosis) and to the patient’s grow entire organs inside MANAGEMENT Chairman Drucker, Yoram 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum EMERGING YEAR FOUNDED 2011 CONTACTS Drucker Yoram Chairman Itamar Shimrat CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Continued... Multikine (Leukocyte Interleukin, Injection) : Phase III Injection) : Interleukin, Multikine (Leukocyte Multikine is an investigational cancer immunotherapeutic agent comprised of a mixture of cytokines (interleukins, and colony stimulating factors) derived from the stimulation in culture of normal chemokines, interferons, Multikine Manufacturing was fully developed and validated at a cost of about $100 million. immune system cells. is currently being tested in a global Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. Phase I Injection) : Interleukin, Multikine (Leukocyte Multikine is an investigational immunotherapeutic agent comprised of a mixture of cytokines (interleukins, and colony stimulating factors) derived from the stimulation in culture of normal chemokines, interferons, It is currently at being tested in a Phase 1 clinical trial in San Diego the Naval Medical immune system cells. Agreement (CRADA) Center in collaboration with the US Navy under a Cooperative Research and Development Corporation CEL-SCI www.cel-sci.com FINANCIAL SUMMARY CEL-SCI fiscal year 2014, During CEL-SCI has raised approximately $250 million. Since inception in 1983, CEL-SCI had approximately $8.5 2014, As of September 30, raised net proceeds of approximately $31.5 million. the Company million. raised another $7 In October 2014, million in cash on hand. PROFILE COMPANY immunotherapyCEL-SCI is a Phase III cancer company with platform technologies that potentially can treat a CEL-SCI is conducting a 20 country III trial of Multikine (Leukocyte Phase diseases. variety of cancers and viral for the treatment advanced primary of head and neck investigational its lead new drug product, Interleukin Inj.), the standard therapies, ahead of These patients as a first treatment receive Multikine following diagnosis, cancer. CEL-SCI thereby reducing recurrence and increasing survival. to activate an effective immune response, believes that the activation has the greatest of an intact immune system chance of success and represents by the first standard of care III trial should lead to Multikine becoming A successful Phase far the biggest market. Navy in HIV infected patients with CEL-SCI is also testing Multikine with the U.S. treatment for these patients. Multikine is a mass produced product that attains tumor. specificity when injected near the HPV related diseases. manufacturing facility and produces Multikine for its clinical trials. ft. The Company operates its own 75,000 sq. Pharmaceuticals (Israel and 3 other Teva Corporate countries are: partners with right to sell Multikine in major and several Far Eastern countries). Orient Europharma (Taiwan countries), PRODUCT PIPLINE 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 1983 EMAIL [email protected] [email protected] TELEPHONE +1 703 506 9460 Suite 802 Vienna 22182 USA ADDRESS 8229 Boone Blvd. CONTACT Mr Geert Kersten Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Chief Scientific Officer for the treatment warts in HIV/HPV co-infected men and women. of peri-anal Preclinical CEL-2000 (LEAPS) : Antigen Presentation System) platform developed from our LEAPS (Ligand Epitope CEL-2000 is the lead peptide modulation, T-cell LEAPS is a patented, technology being develop for treatment the of rheumatoid arthritis. peptide epitope deliverytechnology that enables proprietary CEL-SCI to design and synthesize peptide immunogens. Preclinical LEAPS-H1N1-DC : The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 It is the second potential treatment from our developed Flu. and the Spanish Flu (H5N1), Avian Pandemic Flu, LEAPS platform technology. OPPORTUNITIES Multikine CEL-SCI is open to any reasonable that partnership proposals will allow for the development of Multikine into other solid tumors. LEAPS CEL-SCI is open to partnership proposals that will accelerate the development of its LEAPS platform technology. CEL-SCI may be able to develop an effective treatment/vaccine using As long as a disease epitope is available, CEL- The leading candidatethis technology derived from is the rheumatoid arthritis treatment vaccine, LEAPS. 2000. MANAGEMENT President Mr Maximilian de Clara, Chief Executive Officer Mr Geert Kersten, Vice President of Operations Senior Ms Patricia Prichep, Dr Eyal Talor, Affairs Vice President of Regulatory Senior Mr John Cipriano, Immunology Cellular Vice President of Research, Senior Dr Daniel Zimmerman, Corporation CEL-SCI www.cel-sci.com ...continued 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

t back :: next u General Counsel www.enumeral.com Inc. Holdings, Biomedical Enumeral FINANCIAL SUMMARY $21.5 million through a private we raised placement offering public trading on the OTC and began In July 2014, ticker ENUM. Markets (OTCQB) with the PROFILE COMPANY and developing novel antibody immunotherapiesEnumeral is discovering that system attack help the immune diseased cells. Our platform enables rare immune cells from human patients us to study at and measure high resolution our platform Human™, The Power of Harnessing disease-specific manner. drug effects in a patient-specific, provides a basis for candidates developing best-in-class product from a fundamental understanding of how predict Our vision then is to use this human-derived knowledge to better immunotherapies work in each patient. of with the goals which antibody drug candidates are most likely to be effective in a targeted group of patients, reducing side effects and accelerating the drug discovery process. Lag-3), OX40, we are building a pipeline of immunomodulators that target checkpoint proteins (PD-1, Initially, Our near which the body use to prevent runaway that immune responses can prove debilitating or even deadly. as as well term goals include preclinical testing for programs our internal pipeline in our human-driven platform, in other preclinical models. MANAGEMENT Co-Founder Executive Chairman of the Board of Directors and Rydzewski, John J. and Co-Founder Director Chief Executive Officer, President, Ph.D., Tinkelenberg, Arthur H. Accounting Officer Vice President of Finance and Chief Kevin Sarney, and Clinical Sciences Translational Vice President of Ph.D., M. Isabel Chiu, Vice President of Research and Development Ph.D., Nguyen, “Cokey” Anhco Vice President of Business Development Brand, Derek Matthew A. Ebert, 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2010 EMAIL [email protected] ADDRESS One Kendall Square Building 400 – Fourth Floor MA 02139 Cambridge, CONTACTS Ph.D. Tinkelenberg, Arthur H. Officer, Chief Executive President, Director and Co-Founder Derek Brand Vice President of Business Development WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u CSO Erytech SA Pharma www.erytech.com PROFILE COMPANY is a French biopharmaceutical company new prospects for providing cancer ERYTECH in 2004, Created in Lyon particularly with acute leukemia and selected solid tumors. those patients, ERY-ASP/GRASPA®, has developed ERYTECH By encapsulating the asparaginase enzyme in red blood cells, while significantly reducing the side “tumor starvation” an original treatment that cancer cells through targets Acute Lymphoblastic has recently Phase III data announced positive in ERY-ASP/GRASPA® effects for patients. The product is also in Europe. Acute Myeloid Leukemia (AML) Phase IIb clinical trial in Leukemia (ALL) and is in ALL in the USA. in in Phase I/II clinical development The company is also developing other indications and certain orphan indications in solid tumors outside is ongoing and the companyA Phase II study in pancreas cancer is exploring other solid tumor oncology. indications for ERY-ASP. both AML and pancreas cancer, ALL, in has obtained orphan drug designations for ERY-ASP/GRASPA® ERYTECH and (France), and has its own GMP-approved and operational manufacturing site in Lyon in Europe and the USA, a site for clinical production in Philadelphia (USA). AML in Europe with ALL and The company partnership agreements has concluded licensing and distribution for in Israel. TEVA with ALL and for Orphan Europe (Recordati Group), MANAGEMENT CEO Gil Beyen, Godfrin, Dr Yann 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2004 CONTACTS Gil Beyen CEO Godfrin Dr Yann CSO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.immatics.com immatics biotechnologies GmbH biotechnologies immatics FINANCIAL SUMMARY A €14 mn Series 2004/2005: €40 mn Series B 2007: €54 mn Series C 2010: €34 mn Series D 2013/4: €6 mn Non-equity funding total: PROFILE COMPANY immatics biotechnologies company is an independent biopharmaceutical dedicated to the rational development immatics’ therapeutic tumor- vaccines are based on multiple of novel active immunotherapies against cancer. immatics associated peptides (TUMAPs) which specifically stimulatethe immune system against cancer cells. IMA910 for the treatment of colon has currently three products – IMA901 for the therapyrenal cell cancer, of cancer and IMA950 for the treatment clinical investigation of glioma – under in international studies up to phase immatics raised more than € 142 million (US$ 159 million) in private has equity Since its foundation in 2000, 3. MIG funds and Wellington Partners, immatics’ investors include dievini (Dietmar Hopp), in four financing rounds. 85 people and is based in The company has a headcount of appox. Thomas Strüngmann). Impf (Andreas and AT Germany. and Munich, Tuebingen immatics’TUMAPs each proprietary technology platform XPRESIDENT® enables to identify several thousand mass XPRESIDENT® combines year and select the most relevant antigens suitable for tumor type. a particular biochemistry and immunology to create an extremely efficient discovery genomics, engine with an spectrometry, In addition to multi-peptide immunotherapies, TUMAP candidates. unprecedented and rapid output of validated T-cell other immunotherapyTUMAPs can also be used in the development of approaches such as antibodies or receptors. MANAGEMENT CEO Paul Higham, CSO Singh, Harpreet CMO Carsten Reinhardt, CBO Rainer Kramer, 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2000 EMAIL [email protected] TELEPHONE +49 7071 5397-0 ADDRESS 15 Paul-Ehrlich-Str. 72076 Tuebingen Germany CONTACT Dr Paul Higham CEO Managing Director, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u CEO www.immunepharmaceuticals.com Immune Pharmaceuticals Inc. Pharmaceuticals Immune PROFILE COMPANY developing novel, IMNP) applies approach a personalized to treatment, (NASDAQ: Inc. Immune Pharmaceuticals highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. studies for is entering Phase II clinical moderate-to-severe bertilimumab, lead product candidate, The Company’s and severe asthma. disease with additional studies planned for Crohn’s ulcerative pemphigoid, colitis and bullous a second generation antibody drug conjugate The Company is evaluating use of its NanomAb® platform, the with chemotherapeutics profiles in order to enhance their safety and efficacy by delivering the technology, medicines directly cells. to cancer clinical-stage small growing oncology pipeline also includes proprietary antibodies and, The Company’s molecules that have of solid tumors. been shown activity in a variety with its primary research and development facilities in Israel. Immune is headquartered in the U.S., MANAGEMENT Daniel Teper, Vice President and CFO Executive Gad Berdugo, Vice President of Nanotherapeutics R&D Frenkel, Dr Oshrat PRODUCT PIPELINE 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2011 EMAIL [email protected] [email protected] TELEPHONE +1 646 561 8010 ADDRESS 430 East 29th street Suite 940 New York 10016 USA CONTACT Mr Daniel Teper CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u ImmunID www.immunid.com FINANCIAL SUMMARY $ millions in grants. several $5m investments, PROFILE COMPANY immune molecular diagnosticsImmunID is a pioneer of diagnostics aiming to set the global immune standard. The company atT cell repertoire diversity the genomic level. evaluates the Its clinical product ImmunTraCkeR and blue-chip clinical centers and provides testing worldwide to leading is ISO9001/ISO13485 accredited pharmaceutical companies. and ImmunIg are proprietary immune molecular diagnostics test analysing and quantifying ImmunTraCkeR repertoire diversity and ImmunIg measures B-Cell T-Cell measures ImmunTraCkeR immune competence. DNA. repertoire diversity using multi-N-plex qPCR on genomic Current clinical research and confidential cooperations. Sanofi-Pasteur, Current industrial customers are Roche, Asia. US and customers in Europe, MANAGEMENT Chairman and CEO PhD, Bernhard Sixt, Kurt Schmidt, Chief Financial Officer 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2005 EMAIL [email protected] TELEPHONE +33 0 438 785 770 ADDRESS ImmunID parvis Néel Louis 7, BP50 38040 Grenoble France CONTACTS PhD Bernhard Sixt, Chairman and CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Continued... www.imvaccine.com The DepoVax vaccine platform : Phase II platform : vaccine The DepoVax is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant DepoVax™ specific and sustained immune response with the potential for resulting in a strong, to the immune system, platform is flexible and can be used with a broad range of target The DepoVax™ single-dose effectiveness. The technology is designed to be commercially scalable, antigens for preventative or therapeutic applications. with the potential for years of shelf life stability. Phase II DPX-Survivac : DPX-Survivac consists of survivin-based adjuvanting platform. peptide antigens formulated in the DepoVax™ antigen Survivin has been recognized by the National Institute (NCI) as a promising tumor-associated Cancer in solid Survivin is broadly over-expressed because of its therapeutic potential and its cancer specificity. (TAA) Survivin plays an among others. colon and lung cancers, breast, tumors and blood cancers including ovarian, and promoting resistance angiogenesis, tumor-associated supporting essential role in antagonizing apoptosis, Survivin is also a prognostic factor for many cancers and it is found in high to various anti-cancer therapies. T cell The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic percentage of cancer patients. This targeted therapy immune response against cells presenting survivin peptides on HLA class I molecules. attempts to use the immune system to actively search for tumor cells expressing survivin and destroy them. Phase I DPX-0907 : adjuvanting novel DepoVax with Immunovaccine’s DPX-0907 combines seven tumor associated antigens (TAAs) allowing for the creation of a depot effectdelivery upon vaccination that and presents the antigens platform, designed to with DPX-0907 is Treatment adjuvant to the immune system for a prolonged period of time. to recognize the sophisticated white blood cells that play a key role in fighting cancer, T cells, train the body’s Immunovaccine Inc. Inc. Immunovaccine PROFILE COMPANY cancer immunotherapies develops vaccines based on the Company’s and infectious disease Immunovaccine Inc. a patented formulation that exposure of antigens and provides controlled and prolonged platform, DepoVax™ T cell activation therapies for cancer through Immunovaccine has advanced two adjuvant to the immune system. is expected to enter Phase II clinical DPX-Survivac, Lead cancer vaccine therapy, Phase I human clinical trials. also exploring additional with Immunovaccine and glioblastoma (brain cancer), studies in both ovarian cancer The Company is also advancing an studies in other indications lymphoma including and recurrent ovarian cancer. anthrax and Ebola including innovativeinfectious disease pipeline vaccines for respiratoryvirus (RSV), syncytial virus. PRODUCT PIPELINE 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2000 EMAIL [email protected] TELEPHONE +1 902 492 1819 ADDRESS 1344 Summer Street Suite 412 Nova Scotia, Halifax, Canada B3H 0A8 CONTACTS Dr Marc Mansour Chief Executive Officer Kimberly Stephens Chief Financial Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.imvaccine.com Marc Mansour holds a Ph.D. in biology and has completed a Master of Business Administration. He is an expert in vaccinology He is an expert Administration. in biology of Business and has completed a Master Marc Mansour holds a Ph.D. Mansour led the clinical development of the DepoVax™ Dr. Immunovaccine, Since he joined and cancer immunotherapy. soon entering randomized Phase II trials in lead therapeutic cancer vaccine DPX-Survivac, platform and the Company’s He continues to lead represents the company He to the investor and scientific communities. ovarian cancer and glioblastoma. and externally with collaborators and commercial platform, the internal development of vaccines based on the DepoVax™ partners. Chief Financial Officer Kimberly Stephens, than 14 years of financial managementAccountant with more experience across Kimberly Stephens is a Chartered Ms. Stephens works effectively Ms. In her current position as Chief Financial Officer of Immunovaccine Inc., several industries. with the executive team and Board of Directors and is responsible for producing quarterly and annual financial statements strategic and planning related to business activities, evaluation, analysis, budgeting and cash flow projections, and reporting, Her past roles include Director of Finance for a Canadian subsidiary of an international and financing activities. alliances, Advisory group of Assurance and Audit Manager in the and Director of Finance for SolutionInc, Lloyd, Germanischer company, Nova holding positions as director and treasurer of BioNova, Stephens is also an avid volunteer, Ms. PricewaterhouseCoopers. She and most recently was appointed as chairperson of Habitat for Humanity Nova Scotia. Association, Scotia Life Sciences also volunteers with the Big Brothers Big Sisters of Greater Halifax. ...continued programmedT cells become to specifically target and the In doing so, antigens incorporated vaccine. into the By incorporating multiple target antigens, leaving while normal healthy cells unharmed. attack cancer cells, DPX-0907 attempts to attack cancer cells through multiple avenues and potentiallyminimize the cancer cells’ demonstrated abilityand escape to edit the impact of individual antigens. Phase I DPX-RSV : The from Health Canada to intiateDPX-RSV has received clearance in healthy adults. a Phase I clinical study adjuvanting platform proprietary and is initially being DepoVax™ RSV vaccine is formulated in Immunovaccine’s vaccine the DepoVax-based In preclinical studies, developed to protect the elderly population from infection. a potentially severe respiratory virus that predominantly demonstrated the ability to protect animals against RSV, with Immunovaccine plans to initiate the Phase I trial in the first half of 2015, affects the elderly and infants. initial data expected later this year. vaccine in an infectious disease which will be the first clinical trial of a DepoVax-based The Phase I study, will evaluate the safety and immune response profile of the RSV vaccine candidate adults. in healthy indication, will M.D., in Halifax and led by Joanne Langley, Vaccinology conducted at the Canadian Center for The study, The vaccine will be tested at two different vaccine dose levels enroll 40 healthy adults 50 to 64 years of age. response profile safety and immune following one or two and study investigators will assess the vaccine’s being co-funded byThe trial is Immunovaccine and the Canadian Institutes of immunizations of each dose level. Health Research (CIHR). RSV is a respiratory virus that infects the lungs and breathing passages and most commonly affects the elderly, It can be severe in some patients and is the second infants and patients with compromised immune systems. is estimated it Globally, next to influenza. most commonly in older persons, identified cause of viral pneumonia there is currently no Importantly, with 160,000 deaths. that 64 million cases of RSV infection occur annually, Organization Health (WHO) has designated RSV as a World vaccine available for the prevention of RSV and the high-priority target for vaccine development. MANAGEMENT Chief Executive Officer Mansour, Dr Marc Immunovaccine Inc. Inc. Immunovaccine 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2000 EMAIL [email protected] TELEPHONE +1 902 492 1819 ADDRESS 1344 Summer Street Suite 412 Canada Nova Scotia, Halifax, B3H 0A8 CONTACTS Dr Marc Mansour Chief Executive Officer Kimberly Stephens Chief Financial Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u President and Chief Executive Officer www.maxcyte.com MaxCyte, Inc. Inc. MaxCyte, PROFILE COMPANY and manufacturing, development, modificationMaxCyte specializes in cell technologies to enable the discovery, delivery of innovativetherapeutic products. solid tumor and blood cancer clinical Antigen Receptor (CAR) human MaxCyte is enablingmRNA Chimeric six (6) mRNA expands et al at Campana. Univ of Penn and Dr Dario led bystudies including those being Dr Carl June, and manages both B cell aplasia toxicities and cytokine storm CAR therapies to solid tumors, is fully developed, cell loading platform, clinical MaxCyte’s System, Transfection The MaxCyte® GT™ Scalable and is in over one dozen clearance, NIH RAC with an FDA Master File, and commercialized, well validated, of stem cells clinical trials including ten with mRNA and gene editing MaxCyte is entering into clinical trials for a rapid manufacturing Through its internal development efforts, process for mRNA CAR dramatically time and cost. reducing processing VLX systems are being used by most of the top 20 biopharmas for drug small molecule MaxCyte STX and manufacturing. protein development and vaccine discovery, MANAGEMENT Douglas A. Doerfler, Chief Financial Officer M.B.A., Ron Holtz, Cellular Therapies Executive VP, Ph.D., Peshwa, V. Madhusudan 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 1998 EMAIL [email protected] TELEPHONE +1 301 944 1700 ADDRESS 110 Suite 22 Firstfield Road, MD 20878 Gaithersburg, Executive Vice President, Executive Vice President, Cellular Therapies CONTACT Ph.D. Peshwa, V. Madhusudan WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Microbial Robotics Robotics Microbial www.microbialrobotics.com FINANCIAL SUMMARY are a global private Company. We Our first subsidiary acquired in 2014 was by a pubco for $xxMM. we are cash flow positive. With the next subsidiary exit that firm, is in discussion with a pubco global chemical PROFILE COMPANY we develop synthetic biology-basedViruBots™ BactoBots™ (bacteria) and A global biotechnology firm, These organism- (viruses) using open platforms with layers of patented and proprietary technologies. and chemical, energy, and perform functions for the water, sense, build, based MicrobialBots™ produce, pharmaceutical industries. The GeRM An example of a proprietary layer is our consumable Genetics Rights Management (GeRM™) system. ViruBots from theft and release. system is an additive that locks down BactoBots and We partner with industry talk with us. If your firm is a leader in productization or commercialization expert, Platforms/Proprietaryleaders who can lead the monetizing of our Open Layers biotechnologies. PRODUCT PIPELINE revenues Generating BactoBots : ViruBots (genetically enhanced viruses) that are provided as Open BactoBots (genetically enhanced bacteria) and Platforms. An example is our consumable Proprietary layers are then offered as revenue generating products and services. or ViruBots from theft Genetics Rights Management (GeRM) system that the BactoBots and locks down environmental release. Our synthetic biology-based products range from water technologies to therpeutics. When we open a platform with proprietary we place that technology in a layers of products and services, The early within 36 months exit should represent a 5-10X ROI subsidiary and seek to gain an exit with a pubco. of its launch. MANAGEMENT Over 100 years of synthetic biology experience is represented in the Company. and eukaryotic cell biologist, pediatric oncologist, members include PhD/MDs otolaryngology surgeons, Team prokaryotic microbiologists. 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum EMERGING YEAR FOUNDED 2009 TELEPHONE +1 513 252 2901 PO Box 30085 OH 45230 Cincinnati, USA ADDRESS Headquarters: Corporate CONTACT Barkeloo Mr Jason E. CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u VP Corporate Development, CEO Nanobiotix Corp. VP Corporate Development, www.nanobiotix.com Corp Nanobiotix FINANCIAL SUMMARY than €78 million since its creation.Nanobiotix has raised more NANO, Euronext ticker: FR0011341205, regulatedNanobiotix is listed on the market of Euronext in Paris (ISIN: FP). NANO: Bloomberg: PROFILE COMPANY FR0011341205) is a late clinical-stage nanomedicine company pioneering NANO / ISIN: Nanobiotix (Euronext: proprietary technology, first-in-class, The company’s novel approaches for treatment the local of cancer. more efficient treatment cancer for enhances radiotherapy energy with a view to provide a new, NanoXray, NanoXray products are compatible with current radiotherapy treatments and are meant to treat patients. Liver Cancers, Head and Neck Cancer, Sarcoma, Tissue potentially a wide variety of cancers including Soft via multiple routes of administration. etc., Glioblastoma, Breast Cancer, Prostate Cancer, Tissue is currently under clinical development for Soft based on NanoXray, lead product NBTXR3, Nanobiotix’s The company has partnered with PharmaEngine for Sarcoma and locally advanced Head and Neck Cancer. Asia. clinical development and commercialization of NBTXR3 in France and a US affiliate in Cambridge MA created in September, The company has a head quarter in Paris, 2014. PRODUCT PIPLINE Phase II/III NBTXR3 : MANAGEMENT CEO Levy, Laurent CFO Philippe Mauberna, CMO Elsa Borghi, CBO Bernd Muehlenweg, Tricoli, Patrick 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2003 EMAIL [email protected] ADDRESS 210 Broadway Cambridge 01239 USA CONTACTS Dr Patrick Tricoli CEO VP Corp.Dev, Philippe Mauberna CFO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Biopharmaceuticals Navidea www.navidea.com PROFILE COMPANY Navidea a biopharmaceutical company Biopharmaceuticals,is focused with the on Precision Medicine therapeutics agents. and radiopharmaceutical development and commercialization of precision diagnostics, NAV4694, Navidea precision-targeted products and platforms is developing multiple including Manocept™, to help identify the sites and pathways disease and enable of undetected better diagnostic and NAV5001, (technetium Lymphoseek® patient care. ultimately, targeted treatment and, clinical decision-making, accuracy, was approved platform, first commercial product from the Manocept Navidea’s Tc 99m tilmanocept) injection, strategy superior growth is to deliver Navidea’s by and by the FDA in March 2013 the EMA in November 2014. and shareholder return by bringing to market novel radiopharmaceutical agents the Company’s and advancing global partnering and commercialization efforts. pipeline through selective acquisitions, PRODUCT PIPLINE Approved Tc 99m tilmanocept) injection : (technetium Lymphoseek® imagingagent that was approved by the US FDA for guiding sentinel lymph is a receptor-targeted Lymphoseek as well melanoma and certain oral cancers node biopsy in patients with clinically node negativecancer, breast as for lymphatic mapping in patientsfor with solid tumors this procedure is a component of intraoperative which that may contain tumor key lymph nodes adjacent to a primary tumor, In these procedures, management. are identified and biopsied to determine if cancer has spread to these lymph nodes. metastases, Development Manocept™ platform : The Manocept platform offers diagnostic and therapeuticapplications predicated on the ability of the molecules to specificallyexpressed on macrophages target the CD206 mannose receptor and in certain disease states. rheumatoid arthritis, sarcoma, Macrophages are an emerging target in many Kaposi’s disorders including This platform acts as an disease and cardiovascular inflammation. autoimmune infectious disease, tuberculosis, targeted clinical decision-making, engine for purpose-built molecules that may enhance diagnostic accuracy, including while offering the potential to utilize a breadth of modalities, treatment and ultimately patient care, PET and therapeutic compounds. SPECT, Phase 3 : NAV4694 is a PET imaging agent 3 registration with Phase studies underway for use in the imagingNAV4694 and Disease (AD). Alzheimer’s evaluation of patients impairment such as with signs or symptoms of cognitive Phase 3 : NAV5001 is investigational small molecule radiopharmaceutical imaging agent being developed as an aid in NAV5001 disease (PD) and other movement Parkinson’s including the differential diagnosis of Parkinsonian syndromes, (DLB). as well as Dementia with Lewy Bodies disorders, OPPORTUNITIES is a PET imaging agent Phase 3 registration with studies underway for use in the imaging NAV4694 : NAV4694 Disease (AD). Alzheimer’s and evaluation of patients with signs or symptoms of cognitive impairment such as Navidea is looking for a development and commercialization partner. Navidea is looking for commercialization Tc 99m tilmanocept) injection : (technetium Lymphoseek® partners in various countries Ex-US. is investigational small molecule radiopharmaceutical imaging agent being developed NAV5001 : NAV5001 disease (PD) and other including Parkinson’s as an aid in the differential diagnosis of Parkinsonian syndromes, Navidea and is seeking a development Lewy Bodies (DLB). as well as Dementia with movement disorders, commercialization partner. MANAGEMENT President and Chief Executive Officer Gonzalez, (Rick) J. Ricardo Officer Vice President and Chief Scientific Senior C.N.S., F.A.C.N., Ph.D., Cope, O. Frederick Officer Vice President and Chief Commercial Senior Klima, Thomas J. Treasurer and Secretary Officer, Vice President and Chief Financial Executive L. Larson, Brent Global Regulatory Strategy Vice President, Senior Regan, William J. Chief Medical Officer Vice President, Senior Ph.D., M.D., Reininger, Cornelia B. Executive Medical Director M.S., M.D., Tomblyn, Michael Officer Vice President and Chief Business Executive Ph.D., Tulip, Thomas H. 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 1983 EMAIL [email protected] [email protected] TELEPHONE +1 614 793 7500 ADDRESS 5600 Blazer Parkway Suite 200 OH Dublin, 43017 USA Chief Business Officer CONTACT Dr Thomas Tulip Executive Vice President, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u NeoStem, Inc. NeoStem, www.neostem.com PROFILE COMPANY companyNeoStem is a biopharmaceutical pursuing the preservation of human health globally and enhancement treat by or cure disease repairing and replacing of cell based therapeuticsthrough the development that prevent, The business includes the cells and organs and restoring their normal function. damaged or aged tissue, development of novel proprietary cell therapy products as well as a revenue-generating contract development This combination has created organization an with unique capabilities for and manufacturing service business. cost effective development and immediate in-house product generation. revenue and cash flow PRODUCT PIPLINE Phase 3 Trial Clinical NBS20 : FDA approval patient to commence a Phase 3 trial assessing the efficacy of its NeoStem has received U.S. specific cancer immunotherapy DC/TC (irradiated in vitro proliferating autologous melanoma cell line loaded onto an autologous dendritic cell combined with granulocyte macrophage colony-stimulating factor {GM-CSF}) in Track and Fast Assessment (SPA) The study has Special Protocol patients with late stage metastatic melanoma. and the therapy has been awarded Orphan Drug designation. designation, Phase 2/3 Trial Clinical NBS10 : is being lead candidate in its ischemic repair program, the Company’s AMR-001, also known as NBS10, AMI). developed to treat damaged heart muscle following myocardial an acute infarction (heart attack or 2014 at the AMI Phase 2 clinical trial on November 17, NeoStem anticipates released of data from the PreSERVE placebo-controlled double-blind, This 160 patient randomized, Scientific Sessions. Association’s American Heart clinical trial is evaluating NBS10 in patientssegment elevation with post ST myocardial infarction (STEMI). NeoStem seeks to improve Ischemia occurs when the supply of oxygenated the body is restricted. blood in NBS10 is designed oxygen delivery to tissues through the development and formation of new blood vessels. potentially improving to address a significant medical need currentlyfor which there is no effective treatment, and positioning NeoStem to capture share a meaningful longevity and quality of life for those suffering a STEMI, of this worldwide market. Phase 1 Trial Clinical NBS03D : will sponsor NeoStem Tang, Jeffrey Bluestone and Qizhi In collaboration with UCSF and the laboratories of Drs. for the planned Phase 2 trial to Tregs product consisting of polyclonally expanded Treg and manufacture a The collaboration also includes research efforts to develop treat patients newly diagnosed with type 1 diabetes. Kevan and Dr. the Study Director, Bluestone, Dr. products for therapeutic use. Treg the next generation of in Tregs completed the Phase 1 study of autologous University), the Study Principal Investigator (Yale Herold, Association Scientific Sessions in American Diabetes type 1 diabetes and reported the Phase 1 results at the These results are expected to serve as the basis for the initiation of 2014. Chicago being held on June 13-17, http://www.neostem.com/research-and-development/ – See more at: planned Phase 2 study. the Company’s immunemodulation/t-regulatory-cell-program-3/#sthash.SUlJPSVs.dpuf MANAGEMENT Chief Executive Officer and Director David Mazzo, Dr. Chief Financial Officer and Director Vaters, Robert S. Mr. NeoStem Oncology President, Hans Keirstead, Dr. Chief Medical Officer Douglas Losordo, Dr. Chief Scientific Officer Robert Preti, Dr. Human Resources Vice President, David Schloss, Mr. General Counsel Vaczy, Catherine M. Mrs. 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2006 EMAIL [email protected] [email protected] TELEPHONE +1 212 584 4180 ADDRESS 420 Lexington Ave., Suite 350 New York 10170 USA CONTACT Dr Robert Dillman Oncology Vice President, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Vice-President Drug Discovery, Drug Manufacture Vice-President Drug Discovery, OPPORTUNITIES All interested shareholders and investors. MANAGEMENT Executive Chairman CEO, Kelly, Dr Graham Dr Andrew Heaton, Novogen Limited www.novogen.com FINANCIAL SUMMARY Market Cap approx USD $37M PROFILE COMPANY Australian “ NVGN”) and drug-development companyAustralian listed on both the NASDAQ ( Novogen is an Yale a joint venture with CanTx Inc, The Novogen Group includes the US-based “ NRT”). Securities Exchange ( University. ATMs) Anti-tropomyocins ( superbenzopyrans ( SBPs) and the Novogen has 2 drug technology paltforms: the including SBP compounds have cancer tumour, of cells within a been designed to kill the full heterogeniety a trans-membrane electron-transfer pump mechanism oncogene. The molecular target is cancer stem cells. conjunction with standard compounds target the cytoskeleton of the cancer cell and when used in ATM The result in the fatal destruction of the the cancer cell’s chemotherapy drugs such as taxanes and vina-alkaloids, cytoskeleton. PRODUCT PIPELINE Pre-clinical TRX-0025 : primary indication is castrate-resistant Prostate An SBP drug with a high potency against Prostate cancer.The cancer. Pre-clinical TRX-009 : in For brain cancers and melanoma An SBP drug that has a high potency againstthe neural crest. cancers of and brain cancers and Neuroblastoma in CHILDREN. ADULTS, Pre-clinical Anisina : drug candidate to be used to synergie and greatly in increase efficacy of the taxanes and vinca alkaloids ATM An prostae cancer and neuroblastoma in children. melanoma, Chief Scientific Officer Brown, Dr David Chief Operating Officer Ms Cristyn Humphreys, Program Director ATM Dr Justine Stein, Degenerative Diseases Program Director Dr Stephen Palmer, Affairs Director Clinical and regulatoryDr Kimberley Lilischkis, 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 1994 EMAIL [email protected] TELEPHONE +61 2 947 24101 ADDRESS PO Box 2333 NSW Westfield 1635 AUSTRALIA CONTACT Dr Graham Kelly Executive Chairman CEO, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u MANAGEMENT Drug Discovery Partnerships Director, Dr Nadim Shohdy, Office of Therapeutics Alliances, of Therapeutics Office Medicine School of NYU research.med.nyu.edu/office-therapeutics-alliances PROFILE COMPANY is serves OTA as the drug discovery accelerator arm of NYU. Alliances (OTA) Therapeutics The NYU Office of proactive and pragmatic transforming the way its biomedical assets by NYU commercializes adopting a nimble, is being de-risked to enable pipeline projects better prospects forwith partnering Each of OTA’s approach. mostly operatewith a network of CROs and like a virtual biotech We biopharma or investors for startups. hit finding and hit to lead work. focusing on target validation, med chem consultants, ex-pharma independent, etc) to jump in at any stage disease foundations, investors, flexible model allows partners (pharma, our Moreover, drug discovery efforts in a shared risk/reward model. during OTA’s PRODUCT PIPELINE 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum EMAIL [email protected] TELEPHONE +1 212 263 8178 New York, NY 10016 York, New ADDRESS NYU Langone Medical Center and School of Medicine 550 First Avenue CONTACT Dr Nadim Shohdy Discovery Drug Director, Partnerships EMERGING WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Therapeutics Pelican www.pelicantherapeutics.com FINANCIAL SUMMARY costimulatoryT cell antibodies forPelican is a privately biotechnology funded company developing best-in-class immuno-oncology. PROFILE COMPANY T-cell privately funded biotechnology company best-in-class developing Therapeutics a virtual, is Pelican costimulatory for antibodies immuno-oncology. PIPELINE PRODUCT Pre-Clinical : Antibody Agonistic Monoclonal PTX-25 / costimulator for T-cell a TNFRSF25 monoclonal antibody being developed as anti-human agonistic, A humanized, ICOS) in being GITR, 4-1BB. T cell costimulators (OX40, TNFRSF25 is differentiated from other use in oncology. T cells. highly specific to memory CD8+ OPPORTUNITIES Pelican is exploring early-stage for partnerships with PTX-25 development and use in early stage combination immunotherapy trials. MANAGEMENT CEO Hornblower, Josiah C. CSO H. Schreiber, Taylor 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum EMERGING EMAIL [email protected] CONTACTS Hornblower Josiah C. CEO Schreiber H. Taylor CSO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Pharmaceuticals Rexahn www.rexahn.com COMPANY PROFILE COMPANY RNN) is a clinical stage company biopharmaceutical focused on (NYSE MKT: Inc. Rexahn Pharmaceuticals drugs have cancer been shown to Rexahn’s therapeuticsdeveloping best-in-class for the treatment of cancer. demonstrating efficacy and reduced toxicity. increased directly while bypassing target cancer cells healthy cells, These drug candidates are effective against they multiple drug resistant cancers and show can work together nanotechnology-based drug delivery The Company’s with FDA approved cancer treatments to increase efficacy. systems have shown they make FDA approved can chemo drugs more effective. PRODUCT PIPELINEE Trial Phase I Clinical SupinoxinTM (RX-5902) : Supinoxin is an orally administered highly anti-cancer small molecule that potent first-in-class eliminates cancer Studies to date have shown it cells through inhibition of phosphorylated p68 which isfound only in cancer cells. kidney pancreas. and cancers of the ovary, to be effective in tumor progression and metastasis for melanoma, designed to This trial is a multi-center study, APhase I clinical trial with Supinoxin in cancer patients is ongoing. and maximal tolerated dose-limiting toxicities dose (MTD) and preliminary efficacy tolerability, evaluate the safety, Depending upon the number of dose groups needed to determine the MTD, in patients with solid tumors. half of 2015. Rexahn expects to complete this trial in the first Trial Phase I Clinical RX-3117: RX-3117 is a Next Generation cancer cell specific cytotoxic agent that inhibits DNA and RNA synthesis and induces apoptotic cell death specifically in cancer cells a mechanism distinct from other DNA synthesis by Preclinical studies have shown it be effective in inhibiting the growth of solid tumors in the pancreas, inhibitors. has also shown RX-3117 renal and others and to be effective in gemcitabine resistant cancer cells. colon, lung, which is one of the most widely used chemotherapy efficacy in human cancer cell lines resistant to gemcitabine, An estimated of cancer patients 25 - 40% receiving gemcitabine rapidly become drugs on the market today. An exploratory Phase I clinical trial in cancer patients in 2012 and was conducted in Europe resistant to it. demonstrated that RX-3117 is orally bioavailableadverse events were reported over the dose range and no Rexahn expects to complete an on-going Phase Ib clinical trial in cancer patients with solid tumors in tested. dose-limiting tolerability, designed to evaluate the safety, study, This trial is a multi-center the first half of 2015. toxicities and maximal tolerated dose (MTD) and preliminary efficacy in patients with solid tumors. Trial Phase IIa Clinical Archexin®: Archexin® is a unique anti-cancer drug candidate which inhibits the activated form of the cancer cell signaling survival, protein phosphorylated-Akt1 which is only found in cancer cells and is involved in cancer cell growth, has completed a Phase I clinical trial in cancer patientsArchexin and was and drug resistance. angiogenesis, In a small Phase IIa trial The dose-limiting toxicity was grade three sedation. shown to be safe and well tolerated. Archexin in combination with gemcitabine was shown to be safe and in advanced pancreatic cancer patients, well tolerated and demonstrated a preliminary signal with a median survival efficacy of 9.1 months compared Rexahn initiated an to the historical survival data of 5.65 months for single agent standard gemcitabine therapy. Rexahn additional Phase IIa clinical trial in cancer patients with metastatic renal cell carcinoma in January 2014. expects to complete the initial safety component of this study in early 2015. PC RX-21101 : a RX-21101 is a nano-polymer anticancer drug that combines its nano-drug delivery system with docetaxel, may RX-21101 bolster efficacy while lowering toxicity of FDA approved widely used FDA approved chemo drug. Potential indications include breast, chemo drugs by specific tumor targeting and increased stability in the body. prostate and lung cancer. ovarian, MANAGEMENT Chief Executive Officer Ph.D., Suzdak, Peter D. Mgt., Chief Financial Officer D. Jeong, Ted President & COO MBA, Soni, Rick 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2001 EMAIL [email protected] [email protected] [email protected] TELEPHONE +1 240 268 5300 ADDRESS 15245 Shady Grove Road, Suite 455 MD 20850 Rockville, Chief Executive Officer Mgt. D. Jeong, Ted Chief Financial Officer MBA Rick Soni, President & COO CONTACTS Ph.D. Suzdak, Peter D. EMERGING WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u VP, R&D VP, SolaranRx, Inc. SolaranRx, www.solaranrx.com FINANCIAL SUMMARY perform regulatory testing and conduct clinical SolaranRx is seeking private to scale-up manufacturing, equity Initial funding of platformstudies of our peptide radiopharmaceutical to demonstrate patients. proof of concept in for$3 million is being sought exploratory an to demonstrate clinical study using SRX-1177 receptor targeting in This success will enable 1/2a clinical study to demonstrate a subsequent Phase metastatic melanoma patients. safety and preliminary efficacy of a therapeutic dose using SRX-1177 for metastatic melanoma patients. SolaranRx estimates this milestone and achieve to investment of $7 to $8 million will be needed an additional fund company operations. PROFILE COMPANY is an early stage company to develop a new class of therapies driven and companion imaging Inc. SolaranRx, Our novel peptide technology demonstrates a highly specific agents for the treatment of metastatic melanoma. suitability and then provide a highly targeted binding to melanoma cells enabling patient’s clinicians to predict a delivery of a therapeutic radiopharmaceutical. PRODUCT PIPLINE Pre-Clinical SRX-1177 : In combining both therapeutic and diagnostic capacities. is a theranostic, SRX-1177, lead product, SolaranRx’s the patient is injected with a low dose to determine if they have the targeted MC1 receptor (via diagnostic use, delivering therapeutic same drug, doses of the patients receive higher, If this is the case, SPECT/CT imaging). This ability to targeted radiation tissue. impact on surrounding healthy to the melanoma tumors with minimal Good candidates as time is the enemy for patients with melanoma. identify suitable patients quickly is important, can be treated and others can move rapidly to other therapies. MANAGEMENT President & CEO Mr Les Stewart, Chief Business Officer Dr Mary Ortner, Dr Patricia Williams, Board Chair Dr Stuart Rose, 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FOUNDED 2014 EMAIL [email protected] ADDRESS NE 5901 Indian School Road Albuquerque 87110 USA CONTACT Mr Les Stewart President & CEO EMERGING WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Continued... 27,000,000 15,000,000 $5,000,000 $0.18 TPIV 100: HER2/neu Breast Cancer : Phase I Applicable to ~84% Set of 4 HER2/neu Class II peptide antigens discovered in HER2/neu breast cancer patients. HER2/neu breast cancer population. have shown antigens to be safe and to produce MN, Rochester, Successful Phase I studies at Mayo Clinic, Phase II One arm of Program is ready to move into Phase II. immune responses in all patients evaluated. Inc. TapImmune www.tapimmune.com FINANCIAL SUMMARY Capital Structure Shares Outstanding Public Float Market cap Stock Price PROFILE COMPANY is a clinical stage immunotherapy company with a set of peptide and nucleic acid technologies for TapImmune Its technologies can WA. The Company is based in Seattle, the treatment of cancer and infectious disease. Lead and can also enhance antigen presentation. (CD8) cells T-killer (CD4) and T-helper broadly stimulate programs and breast cancer. are in HER2/neu breast cancer and in ovarian The Company antigen technologies has an exclusive option to license peptide from the Mayo Foundation for PolyStart) are owned Proprietary presentation antigen enhancing technologies (TAP; Education and Research. The Company’s The technologies are widely applicable to cancer and infectious disease. TapImmune. by development pipeline is focused on cancer. Succesful Phase I studies have to be safe and to stimulate shown peptide antigens immune responses in These programs are ready to move into Phase II with the first Phase II study the majority of patients treated. 2015. scheduled to start in Q2, The Company plans to take programs development partnerships Phase II clinical but will seek into and through for current clinical programs and for PolyStart. PRODUCT PIPELINE 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum EMAIL [email protected] TELEPHONE +1 206 504 7280 ADDRESS E Suite 100. Ave 1551 Eastlake WA 98102. Seattle, USA CONTACT Glynn Wilson, Ph.D. Chairman & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Consultant Medical Director Chairman & CEO Head of Research Ph.D., Bob Florkiewicz, MBA, Strategic Advisor Ph.D., John Bonfiglio, MD,, Yeramian, Patrick Advisor & Director Development Mark Reddish, ...continued 101 which is a novel Class I antigen thatTPIV effective is 4-5 times more at killing human studies will include than Neuvax. breast cancer cells in culture believe that the combination approach comprehensive Class I and Class II antigens provides the most of for a We HER2/neu immunotherapeutic forAntigens can also be used treatment of ovarian and colorectal cancer. & breast cancer : Phase I/II TPIV 200: Ovarian Set of 5 Class II antigens against folate is overexpressed in ~90% ovarian cancers and in receptor alpha which ~80% triple negative breast cancers. Completion of successful Phase I has shown that are safe and produced immune responses in 20 the antigens Phase II is scheduled to start 16 of these patients showed a long-term response. out of 21 evaluable patients. TPIV 200 to prevent recurrence in triple This will be a multi-center study to evaluate the ability of 2015. in Q2, negative breast cancer patients. PolyStart PolyStart is a proprietary DNA expression vector with two functional domains” initiation sites sequential, PolyStart which has multiple, 1. encodes a variety of antigens which Array (PAA) Antigen Poly 2. Peptides expressed from PolyStart are naturally inside cells with 4-5 more peptide being expressed processed PolyStart can be delivered as a DNA plasmid or in a viral vector. than is normally possible. TPIV 200. TPIV 100/101 and strategy for “boost” PolyStart is being developed as a Strong patent position. OPPORTUNITIES TPIV 100/101: HER2/neu breast cancer TPIV either alone or in combination with other immunotherapies. Partnership possibilities for Ovarian & breast cancer TPIV 200: TPIV 200 either alone or in combination with other immunotherapies. Partnership possibilities for PolyStart Incorporation of novel tumor antigens into Partnership/outlicensing possibilities in cancer and infectious disease. our current programs. MANAGEMENT Glynn Wilson, Ph.D., Inc. TapImmune www.tapimmune.com 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer

3rd Annual 3rd Cancer Bio Partnering & Investment Forum EMAIL [email protected] TELEPHONE +1 206 504 7280 ADDRESS E Suite 100. Ave 1551 Eastlake WA 98102. Seattle, USA Chairman & CEO CONTACT Glynn Wilson, Ph.D. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Continued... Oncoquest-CLL (autologous therapeutic vaccine) : Phase Ib clinical trial. : Phase Ib clinical Oncoquest-CLL (autologous therapeutic vaccine) leukemic antigens found in a cell lysate in a synthetic AGGREGON with high dose rhIL-2 and totality of patient’s multi-membrane unit structure. Chronic lymphocytic leukemia Clinical indication: trial : Pilot Phase II clinical Oncoquest-L (autologous therapeutic vaccine) lymphoma antigens found in a cell lysate in a synthetic AGGREGON with high dose rhIL-2 and totality of patient’s multi-membrane unit structure. follicular lymphoma Non-Hodgkin’s Clinical indication: : R&D; Preparing for Phase I/II submission Oncoquest (autologous therapeutic vaccine) tumor antigens found in a cell lysate in a synthetic AGGREGON with high dose rhIL-2 and totality of patient’s multi-membrane unit structure. Acute Myeloid leukemia) and Solid tumors Hematological malignancies (Multiple Myeloma, Clinical indication: ovarian cancer). colorectal cancer, lung cancer, (e.g. XEME Biopharma Inc. Biopharma XEME www.xemebiopharma.com FINANCIAL SUMMARY LabsInc.) and an ongoing investment Investments to date $7.5 MM from the parent company include (TheraTest platform technologyprogressed was developed and to proof of concept XEME Biopharma’s of $1.5 MM/year. also has access to XEME Finally, studies at Oncothyreon) at Biomira USA (now the cost of about $20 MM. non-dilutive sources of capital with Cancer partnership (NIH SBIR/STTR mechanisms and the current clinical America). Centers of Treatment PROFILE COMPANY Labs Inc.) is a clinical stage company TheraTest (a wholly owned subsidiary of XEME Biopharma Inc. currently therapeutic pursuing pilot Phase I and II trials of autologous vaccines in hematologic malignancies in situ vaccination products “off-the shelf” XEME has Additionally, (OncoquestTM-L and OncoquestTM-CLL). products have XEME’s (OncolipinTM) for intra-tumoral (IT) treatment of operable inoperable and solid tumors. demonstrated safety and indicated clinical trials out of the National efficacy in two previous Cancer Institute. strong IP as well as disruptive manufacturing and cost advantages over With an impressive Management team, vaccine candidates we believe that XEME’s inhibitors, dendritic cell-based autologous vaccines and check-point havebest in class. the potential to become first to market and PRODUCT PIPELINE 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FUNDED 2007 EMAIL Contact@xemebiopharma. com TELEPHONE +1 732 823 1291 ADDRESS XEME Biopharma Inc., 7 Deer Park Drive, Suite M-1, Monmouth Junction, NJ 08852-1921 CONTACTS Dr Mircea Popescu President & CEO Dr Marius Teodorescu Directors Chairman of the Board of Dr Sunil Metkar and Business Research Director, Development WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Synthetic multi-membrane AGGREGON with high dose rhIL-2 for intra-tumoral administration. Synthetic multi-membrane intra-tumoral vaccination of patients with operable bulky or inoperable solid “in situ” For Clinical indication: tumors. MANAGEMENT President and CEO Founder, Ph.D., M.D., Popescu, C. Mircea Founder, Chairman Scientific Advisory Board, Clinical Research Consultant Advisory Board, Chairman Scientific Founder, Ph.D., M.D., Larry Kwak, and Myeloma and Co-Director of the Center for Cancer Immunology Research – Chairman of the Department of Lymphoma Biology Section at the National Vaccine Kwak previously served as Head of the Dr. Anderson Cancer Center. at the M.D. 100 most the world’s one of TIME100, Kwak was named to the Dr. An author of more than 160 articles, Cancer Institute (NCI). TIME magazine in 2010. influential people by Board Chair Ph.D., M.D., Teodorescu, Marius a successful manufacturer and distributor of immunoassay test kits for laboratories Inc., TheraTest – the founder of He graduate students and physicians. taught Immunology to medical students, He manufactured viral vaccines, Rheumatology. review inventions, has more than 120 publications of original work, Teodorescu Dr. also practised Rheumatology for 25 years. Rheumatology and related fields. articles and books in Immunology, – a seasoned Biotechnology executive with a strong research and development background. Previously, he was President Previously, – a seasoned Biotechnology executive with a strong research and development background. General Manager of Biomira USA and a Scientific Founder and Vaccines, Wyeth Research Fellow at of Oncotherapeutics, journals Popescu has published extensively in peer-reviewed Dr. NJ. The Liposome Company of Princeton, Executive Director of patents. and holds numerous U.S. QC Vice President R&D and Founder, Ph.D., Robb, J. Richard He manufactured the first biotechnology-derived IL-2 while working at technology platform. – the co-inventor of XEME’s was co- reviews and book chapters, He has published numerous scientific articles, DuPont for use in clinical trials at NCI. author on two issued US patents and Principal Investigator on two NCI grants. Director of Manufacturing William Reilley, process development, manufacturing, – has a thorough and comprehensive experience in pharmaceutical/biopharmaceutical Bill held Director level positions (now Glaxo at Smith-Kline Beecham and sterile filling experience. tech transfer, scale-up, Biomira USA and Insmed. The Liposome Company, J&J, Smith-Kline), ...continued OPPORTUNITIES Pre-clinical : therapies Oncoquest + Combination tumor antigens found in a cell lysate in a synthetic rhIL-2 and totality of patient’s AGGREGON with high dose in combinationmulti-membrane unit structure with other therapies. Hematological and Solid tumors malignancies Clinical indication: IND stage : Active Immunotherapy) Non-autologous on-the-shelf product, Oncolipin-IT (In situ vaccination; XEME Biopharma Inc. Biopharma XEME www.xemebiopharma.com 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum YEAR FUNDED 2007 EMAIL [email protected] TELEPHONE +1 732 823 1291 ADDRESS XEME Biopharma Inc., 7 Deer Park Drive, Suite M-1, Monmouth Junction, NJ 08852-1921 CONTACTS Dr Mircea Popescu President & CEO Dr Marius Teodorescu Directors Chairman of the Board of Dr Sunil Metkar and Business Research Director, Development WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.berlinpartner.de First choice: Berlin Partner for Business and Technology for Business First choice: Berlin Partner investors and scientific institutions in Business and technology support for companies, With GmbH mission. Technologie Wirtschaft und Partner für Berlin – this is the Berlin our many experts customized services and research network, and an excellent science expand innovate, provide an outstanding range of programs to help companies launch, and secure their economic future in Berlin. Technology Berlin Partner for Business and A unique public-private partnership, collaborates with the Berlin State Senateover 200 companies dedicated and to promoting responsible for Berlin Partner is also marketing the German capital to the world, their city. campaign. “be Berlin” for example with the successful Berlin Partner Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.biodeutschland.org As the sector association of the biotechnology industry, BIO Deutschland has of the biotechnologyAs the sector association industry, development of an of supporting and promoting the set itself the objective on modern biosciences. economic sector based innovative It is run by a board of ten The Berlin-based association currently 300 members. has over as well members consisting of CEOs and managing directors of biotechnology companies, This committee comprehensively various fields represents the as directors of BioRegions. in the sector. are organised in working groupsThe member companies and their experts that deal with finance and taxation; licences and technical contracts; regulatory the following topics: matters; innovation German-US cooperation; and entrepreneurship; HR; policy; health Using a wide range of competition and regulatory policy; technology transfer; and PR. BIO Deutschland lobbies for legal parameters for improvements to the political initiatives, innovative small and medium-sized enterprises. biotechnology sector representative at the European BIO Deutschland is Germany’s BIO Deutschland also works closely with other biotech in Brussels. EuropaBio, association, organisations in Europe and the USA in order to lobby for of the sector in the interests The association is also very active in a broad range an internationally coordinated way. of events with the aim of providing biotechnology with a platform forand discussion interaction. BIO Deutschland Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.biotechgate.com Your source for life science companies and licensing information. for life science companies source Your If you are about to negotiate company. deal between a Biotech and a Pharma a licensing Or Or you are looking for Pharma company a big to out-license your Biotech product. medical technologyyou are active in the sector and just want to identify (Medtech) for Or you are an investor looking investment potential cooperation partners or customers. aboutopportunities - or you just want to know historical financing rounds and valuations in This portal can solve all of these Pharam and medical device field. Biotech, the life sciences, problems – and even more. Biotech Gate Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.edisongroup.com Edison is a UK-based investment intelligence firm.Edison is a UK-based York, New 70 equity analystsIt employs more than operating in London, from offices and Frankfurt that coverage provides research on more than 700 Wellington Sydney, the largest dedicated making it one of and mid-cap small publicly traded companies, Healthcare is the largest industry group within Edison with 12 research providers worldwide. Continental analysts covering some 150 biotech/medical device companies located in UK, Europe, North America and Australia. Edison Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.freemindconsultants.com Tel: (617) 648-0340 (617) 648-0340 Tel: (617) 904-1767 Fax: [email protected] Email: Boston FreeMind Group #124 Ave. 423 Brookline MA 02215 Boston, DC Washington FreeMind Consultants 4094 Majestic lane # 269 VA 22033 Fairfax, Jerusalem FreeMind Group Center Tech Hi - Hebrew University Jerusalem 95702 Israel FreeMind is a consulting group whose goal is to assist its clients in maximizing in its clients group whose goal is to assist FreeMind is a consulting in Established funding from non-dilutive sources. their potential to receive with over largest consulting group of its kind FreeMind is the 400 active 1999, proven long-term strategic FreeMind’s academics and Industry alike. clients, over to date. 1.5 billion dollars its clients approach has garnered Our expertise in applying for grants extends throughout every and contracts government FDA, NSF, DoD, including all NIH institutes, mechanism open to funding the life sciences Bill and Melinda as well as private foundations J Fox, such as Michael etc., BARDA, CDC, Gates and Susan G Komen. Analysts and Project Managers are knowledgeable team of and experienced FreeMind’s dedicated to guiding its clients non-dilutive funding efforts from identification the most of Our team of experts suitable opportunity through to submission and subsequent award. funding a keywill assist our clients in making non-dilutive tool in their long-term financial strategy. FreeMind Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.lifesciences.instinctif.com Instinctif Partners is an international business communications consultancy. business communications consultancy. is an international Instinctif Partners the Life Sciences practice delivering trulyWith a track record of creative programmes, partnerships focuses the value proposition for on enhancing seeking investment, companies with clients to communicate Our core skill is working the value of their or customers. crafting science and innovation to key most relevant channels: stakeholders through the Specifically, product or technology. communications solutions that showcase each company, financial, we are unique in offering specialist expertise seamlessly across corporate, industry, healthcare and marketing communications with outreach programmes to media, financial and investment communities. public, professional, Our service offering covers all communications disciplines including strategic counsel, internal communications, crisis communications, public affairs, media relations, IR, PR, Our globally research and event management. design, copywriting, advertising, marketing, integrated and dedicated life sciences team serves from our bases clients around the world Melbourne and Sydney. Boston, Munich, Manchester, in London, Instinctif Partners Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u http://labiotech.eu LaBiotech.eu is the free and extensive European biotechnology news website. news website. biotechnology European and extensive is the free LaBiotech.eu dynamic media is the best way this young and for you 2014, Launched in September to our Thanks to keep a watch and innovations on the business of biotechnologies. your dedicated european biotech events we are also partnerships with major website for subscribe to our weekly can also newsletter to receive You event summaries and agenda. the latest news. LaBiotech.eu Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.lifesciencenation.com Life Science Nation (LSN) accelerates the business of early stage life science via (LSN) accelerates the business of Life Science Nation sourcing platform. a Match.com-like This platform enables executives to find firms that are a fit for their business profile. Professionals leverage to generate LSN prospects, a global target list (GTL) of qualified LSN researches and curates market intelligence on greatly enhancing marketing efficiency. which by their emergingThe first is biotech and medtech companies, two industry sectors: LSN tracks ten categories of Second, ephemeral nature are challenging to find and track. early stage left and identifies who is filling the void life science investors by venture capital. LSN has developed unique methodologies for tracking and keeping up-to-date with both of these dynamic market segments. LSN created and managesEarly the successful Redefining Stage (RESI) Investments which brings together global early stage and medtech companies biotech conference series, The Life Science LSN has also written and published a book, with early stage investors. with a Next Phase, Fundraising Manifesto as well as a weekly newsletter, Executive’s a Fundraising Boot Camp at LSN presents conferences Finally, readership of 15,000. messaging, branding, and provides seminars on and partnering events around the globe outbound marketing and sales to incubators and venture development centers within the life sciences. Life Science Nation Life Science Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.onenucleus.com One Nucleus is a membership organisation for international life science and for international life science is a membership organisation One Nucleus the heart of London UK, are based in Cambridge and We healthcare companies. and healthcare cluster. largest life science Europe’s and the top European life science For One Nucleus and our members to be Vision: healthcare network. will achieve this by of our members. maximising the global competitiveness We Mission: One Nucleus is a and formerly known as ERBI, Established in 1997, History: Organisation membership organisation and located in Cambridge and London – the centre not-for-profit, leading life science and healthcare cluster. of Europe’s biotech, The company has over 470 organisations including pharmaceutical, as members medical device and diagnostic companies and associated service technical and commercial providers. For our our members. of mission is to maximise the global competitiveness One Nucleus’s that means being global leaders in the research, science and technology-based members, development and commercialisation of healthcare innovations that radically the improve professional services For our business and lives around the world. quality of people’s it means delivering exceptional services that significantly enhance the business members, performance of their clients. One Nucleus Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.swissbiotech.org SwissBiotech – One Nation – One Biotech Cluster SwissBiotech – One BaselArea, the fourSwiss Biotech unites regions leading biotech (BioAlps, of Switzerland regionsThe have early on combined efforts with Area). and Greater Zurich Ticino Biopolo life-science listings leading position in terms of the SWX Swiss Exchange which holds a and services. Association Represents more Association named Swiss Biotech The National Industry than 150 companies to date and acts as the operational arm for the marketing alliance. profile as an economic center in Europe and profiles Swiss Biotech raises Switzerland’s the biotech industry its key with research institutions and companies. messageSwiss Biotechs’ mission is to spread the of Switzerland as one of the top This will be achieved by presenting a comprehensive biotech locations in the world. finance economics, education, picture of the drivers of biotechnology including research, The bases for success in biotechnology of research are the critical mass and industry. The early integration of industry and institutes and accelerated technology transfer. More well-trained workforce is another critical success factor for rapid economic growth. than 40 technology parks throughout the country support the increasingly important and process. successful TechTransfer Further inquiries: Executive Office SwissBiotech, +41 (0)44 455 56 78 Tel. [email protected] Swiss Biotech Association Swiss Biotech Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.tiberendstrategicadvisors.com 1. To enhance valuation To 1. build visibility for partnerships and strategic alliances To 2. Tiberend Strategic Advisors, Inc. Advisors, Strategic Tiberend 5th Floor, 35th Street, W. 35 NY 10001-2205 York, New 212.827.0020 Tel: 212.827.0028 Fax Fax: Tiberend Strategic Advisors, Inc. is a corporate communications firm providing a corporate communications firm is Inc. Strategic Advisors, Tiberend companies – biotech (therapeutics), for life science media strategy and execution diagnostics. medical devices and work with both public and private emerging growth companies: We Tiberend Strategic Advisors, Inc. Advisors, Strategic Tiberend Sponsors and Supporters and Sponsors 3rd ANNUAL 3rd Forum & Investment Bio Partnering Cancer 3rd Annual 3rd Cancer Bio Partnering & Investment Forum 3rd ANNUAL Cancer Bio Partnering & Investment Forum WELCOME Organisers

Sachs Associates www.sachsforum.com

Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each SPEAKERS year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions. The benefits of conference participation with Sachs Associates may be summarised as follows: Multimedia Exposure Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies, including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established

relationships with other financial press organisations globally, which allow further effective distribution on PRESENTING COMPANIES behalf of its clients. Eminent Speakers Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior political and economic personalities as speakers at its events. Sponsorship and Marketing Opportunities for forthcoming events Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. SUPPORTING ORGANISATIONS All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events. The following sponsorship and marketing opportunities are available at future conferences: • Conference Sponsor – including workshops and social events • Exhibition stands • Distribution of Promotional Material If your company is interested in exhibiting or sponsorship opportunities please call Silvia Kar on +44 203 463 4890. ORGANISERS

3rd Annual Cancer Bio Partnering & Investment Forum WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

27 Belsize Lane 8th Annual 3rd Annual 3rd London NW3 5AS 15th Annual Tel: +44 (0)203 463 4890 +44 (0)203 Tel: Fax: +44 (0)207 691 7919 Fax: www.sachsforum.com/basel15 29th May 2015 • Chicago • USA Biotech in Europe Forum Biotech in Europe www.sachsforum.com Sachs Immuno-Oncology: Sachs Immuno-Oncology: www.sachsforum.com/zurich_elsceo15 BD&L and Investment Forum BD&L and Investment We look forward to seeing you at: forward to seeing you look We For Global Partnering & Investment Global Partnering For 16th November 2015 • Düsseldorf • Germany 2015 • 16th November Follow us on Twitter – @SachsAssociates Twitter us on Follow 03rd – 04th March 2015 • Hilton Zurich Airport Hotel 2015 • Hilton Zurich – 04th March 03rd Review the 2014 Forum: www.sachsforum.com/mdis14 29th – 30th September 2015 • Congress Centre Basel Centre 29th – 30th September 2015 • Congress Medtech & Diagnostics Innovations Summit Medtech & Diagnostics Innovations

Partnering & Investing In Biotech & Pharma Industry & Investing In Biotech & Pharma Partnering European Life Science CEO Forum & Exhibition Life Science CEO Forum European 3RD ANNUAL SACHS CANCER BIO PARTNERING & INVESTMENT FORUM INVESTMENT & PARTNERING BIO CANCER SACHS ANNUAL 3RD